<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="EN" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Environ Sci Technol</journal-id><journal-id journal-id-type="iso-abbrev">Environ Sci Technol</journal-id><journal-id journal-id-type="pmc-domain-id">822</journal-id><journal-id journal-id-type="pmc-domain">acssd</journal-id><journal-id journal-id-type="publisher-id">es</journal-id><journal-title-group><journal-title>Environmental Science &amp; Technology</journal-title></journal-title-group><issn pub-type="ppub">0013-936X</issn><issn pub-type="epub">1520-5851</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>ACS AuthorChoice</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10720383</article-id><article-id pub-id-type="pmcid-ver">PMC10720383.1</article-id><article-id pub-id-type="pmcaid">10720383</article-id><article-id pub-id-type="pmcaiid">10720383</article-id><article-id pub-id-type="pmid">38008925</article-id><article-id pub-id-type="doi">10.1021/acs.est.3c07077</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group><subject>Article</subject></subj-group></article-categories><title-group><article-title>Acetylcholinesterase
Inhibition in Rats and Humans
Following Acute Fenitrothion Exposure Predicted by Physiologically
Based Kinetic Modeling-Facilitated Quantitative <italic toggle="yes">In Vitro</italic> to <italic toggle="yes">In Vivo</italic> Extrapolation</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="ath1"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0925-8492</contrib-id><name name-style="western"><surname>Chen</surname><given-names initials="J">Jiaqi</given-names></name><xref rid="cor1" ref-type="other">*</xref></contrib><contrib contrib-type="author" id="ath2"><name name-style="western"><surname>Zhao</surname><given-names initials="S">Shensheng</given-names></name><xref rid="notes2" ref-type="notes">#</xref></contrib><contrib contrib-type="author" id="ath3"><name name-style="western"><surname>Wesseling</surname><given-names initials="S">Sebastiaan</given-names></name></contrib><contrib contrib-type="author" id="ath4"><name name-style="western"><surname>Kramer</surname><given-names initials="NI">Nynke I.</given-names></name></contrib><contrib contrib-type="author" id="ath5"><name name-style="western"><surname>Rietjens</surname><given-names initials="IMCM">Ivonne M.C.M.</given-names></name></contrib><contrib contrib-type="author" id="ath6"><name name-style="western"><surname>Bouwmeester</surname><given-names initials="H">Hans</given-names></name></contrib><aff id="aff1">Division of Toxicology, <institution>Wageningen University and Research</institution>, Stippeneng 4, Wageningen 6708 WE, <country>The Netherlands</country></aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Email: <email>jiaqi.chen@wur.nl</email>.</corresp></author-notes><pub-date pub-type="epub"><day>27</day><month>11</month><year>2023</year></pub-date><pub-date pub-type="collection"><day>12</day><month>12</month><year>2023</year></pub-date><volume>57</volume><issue>49</issue><issue-id pub-id-type="pmc-issue-id">451034</issue-id><fpage>20521</fpage><lpage>20531</lpage><history><date date-type="received"><day>29</day><month>08</month><year>2023</year></date><date date-type="accepted"><day>14</day><month>11</month><year>2023</year></date><date date-type="rev-recd"><day>11</day><month>11</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>14</day><month>12</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>15</day><month>12</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-01-29 01:25:23.487"><day>29</day><month>01</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2023 The Authors. Published by American Chemical Society</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>The Authors</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="es3c07077.pdf"/><abstract><p content-type="toc-graphic"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="ab-tgr1" position="float" orientation="portrait" xlink:href="es3c07077_0008.jpg"/></p><p>Worldwide use of
organophosphate pesticides as agricultural chemicals
aims to maintain a stable food supply, while their toxicity remains
a major public health concern. A common mechanism of acute neurotoxicity
following organophosphate pesticide exposure is the inhibition of
acetylcholinesterase (AChE). To support Next Generation Risk Assessment
for public health upon acute neurotoxicity induced by organophosphate
pesticides, physiologically based kinetic (PBK) modeling-facilitated
quantitative <italic toggle="yes">in vitro</italic> to <italic toggle="yes">in vivo</italic> extrapolation (QIVIVE) approach was employed in this study, with
fenitrothion (FNT) as an exemplary organophosphate pesticide. Rat
and human PBK models were parametrized with data derived from <italic toggle="yes">in silico</italic> predictions and <italic toggle="yes">in vitro</italic> incubations.
Then, PBK model-based QIVIVE was performed to convert species-specific
concentration-dependent AChE inhibition obtained from <italic toggle="yes">in vitro</italic> blood assays to corresponding <italic toggle="yes">in vivo</italic> dose&#8211;response
curves, from which points of departure (PODs) were derived. The obtained
values for rats and humans were comparable with reported no-observed-adverse-effect
levels (NOAELs). Humans were found to be more susceptible than rats
toward erythrocyte AChE inhibition induced by acute FNT exposure due
to interspecies differences in toxicokinetics and toxicodynamics.
The described approach adequately predicts toxicokinetics and acute
toxicity of FNT, providing a proof-of-principle for applying this
approach in a 3R-based chemical risk assessment paradigm.</p></abstract><abstract abstract-type="short"><p>An integration of PBK modeling-facilitated QIVIVE approach
and <italic toggle="yes">in vitro</italic> blood AChE inhibition assay provides
a 3R-based paradigm for human health risk assessment for organophosphate
pesticide exposures.</p></abstract><kwd-group><kwd>organophosphate pesticide</kwd><kwd>fenitrothion</kwd><kwd>acetylcholinesterase
inhibition</kwd><kwd>physiologically based kinetic (PBK) model</kwd><kwd>quantitative <italic toggle="yes">in vitro</italic> to <italic toggle="yes">in vivo</italic> extrapolation (QIVIVE)</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution>European Commission</institution><institution-id institution-id-type="doi">10.13039/501100000780</institution-id></institution-wrap></funding-source><award-id>101057014</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution>China Scholarship Council</institution><institution-id institution-id-type="doi">10.13039/501100004543</institution-id></institution-wrap></funding-source><award-id>202009370057</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>es3c07077</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>es3c07077</meta-value></custom-meta><custom-meta><meta-name>ccc-price</meta-name><meta-value/></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><label>1</label><title>Introduction</title><p>The
organophosphate pesticide fenitrothion (FNT, <italic toggle="yes">O</italic>,<italic toggle="yes">O</italic>-dimethyl <italic toggle="yes">O</italic>-4-nitro-<italic toggle="yes">m</italic>-tolyl phosphorothioate) (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>) has been widely used for pest control since its synthesis
in 1959.<sup><xref ref-type="bibr" rid="ref1">1</xref>,<xref ref-type="bibr" rid="ref2">2</xref></sup> Usage of FNT (also marketed as Metation,
Folithion, and Sumithion), though prohibited in some countries or
areas (i.e., European Union), is still (restrictively) permitted in
some parts of the world.<sup><xref ref-type="bibr" rid="ref3">3</xref></sup> Due to agricultural
activities and urbanization, a worldwide FNT residue has been reported
in soils, waters, and crops,<sup><xref ref-type="bibr" rid="ref4">4</xref>&#8722;<xref ref-type="bibr" rid="ref6">6</xref></sup> posing health risks for general
populations through food products and drinking water.<sup><xref ref-type="bibr" rid="ref1">1</xref>,<xref ref-type="bibr" rid="ref7">7</xref></sup></p><fig id="fig1" position="float" orientation="portrait"><label>Figure 1</label><caption><p>Major
biotransformation pathways of fenitrothion (FNT) catalyzed
by cytochromes P450 (CYP450s) and paraoxonase 1 (PON1) in rats and
humans.<sup><xref ref-type="bibr" rid="ref1">1</xref>,<xref ref-type="bibr" rid="ref2">2</xref></sup></p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gr1" position="float" orientation="portrait" xlink:href="es3c07077_0001.jpg"/></fig><p>Following oral exposure in mammals, FNT is rapidly and almost completely
absorbed and well distributed over the body especially to the liver
and blood.<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> FNT is predominately cleared
by hepatic cytochromes P450 (CYP450s).<sup><xref ref-type="bibr" rid="ref1">1</xref>,<xref ref-type="bibr" rid="ref2">2</xref></sup> As shown in <xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>, CYP450s are capable
of detoxifying FNT to 3-methyl-4-nitrophenol (MNP) and dimethylthiophosphate
(DMTP), but they also bioactivate FNT to its oxon analogue fenitrooxon
(FNO), which is a more potent inhibitor toward acetylcholinesterase
(AChE) than FNT.<sup><xref ref-type="bibr" rid="ref8">8</xref>,<xref ref-type="bibr" rid="ref9">9</xref></sup> A further paraoxonase 1 (PON1)-catalyzed
detoxification (hydrolysis) of FNO to MNP and dimethylphosphate (DMP)
takes place in both liver and blood. Subsequently, the produced MNP,
DMTP, and DMP from FNT and FNO are excreted from the body via urine.<sup><xref ref-type="bibr" rid="ref1">1</xref>,<xref ref-type="bibr" rid="ref2">2</xref></sup></p><p>Acute exposure to FNT will cause neurotoxic symptoms in mammals
due to AChE inhibition and subsequent acetylcholine accumulation at
synaptic clefts.<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> Several no-observed-adverse-effect
levels (NOAELs) derived from different <italic toggle="yes">in vivo</italic> rat
or human toxicity data sets have been reported by different organizations,
even though the same endpoint (erythrocyte AChE inhibition) was chosen.
Specifically, NOAELs of 0.25 and 1.3 mg/kg BW for rats have been set
by the US Environmental Protection Agency (US EPA)<sup><xref ref-type="bibr" rid="ref11">11</xref></sup> and European Food Safety Authority (EFSA),<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> respectively, and NOAELs of 0.33 and 0.36 mg/kg BW for
humans have been derived by Australian Pesticides and Veterinary Medicines
Authority (APVMA)<sup><xref ref-type="bibr" rid="ref12">12</xref></sup> and the Joint Food
and Agriculture Organization of the United Nations/World Health Organization
Meeting on Pesticide Residues (JMPR),<sup><xref ref-type="bibr" rid="ref13">13</xref></sup> respectively. By further applying uncertainty factors accounting
for the interspecies and/or interindividual differences to these NOAELs,
acute reference doses (ARfDs) have been estimated, ranging from 0.0025
mg/kg BW/day (US EPA)<sup><xref ref-type="bibr" rid="ref11">11</xref></sup> to 0.04 mg/kg BW/day
(JMPR).<sup><xref ref-type="bibr" rid="ref13">13</xref></sup> Due to the large variations among
these ARfDs, additional studies are necessary to derive a point of
departure (POD) to support the risk assessment for acute FNT exposure.</p><p>New approach methodologies are currently explored in accordance
with the principles of Next Generation Risk Assessment for chemical
exposures to reduce the reliance on animal approaches.<sup><xref ref-type="bibr" rid="ref14">14</xref>,<xref ref-type="bibr" rid="ref15">15</xref></sup> As an example, physiologically based kinetic (PBK) modeling-facilitated
quantitative <italic toggle="yes">in vitro</italic> to <italic toggle="yes">in vivo</italic> extrapolation (QIVIVE) has been widely employed for the prediction
of the <italic toggle="yes">in vivo</italic> toxicity of chemicals with various
endpoints,<sup><xref ref-type="bibr" rid="ref16">16</xref>,<xref ref-type="bibr" rid="ref17">17</xref></sup> including AChE inhibition following
acute exposure to organophosphate pesticides in both rats and humans.<sup><xref ref-type="bibr" rid="ref18">18</xref>&#8722;<xref ref-type="bibr" rid="ref21">21</xref></sup> PBK models mathematically describe the body tissues as interconnected
compartments linked by the blood, and can simulate time profiles of
chemical concentrations in tissues under certain dose levels.<sup><xref ref-type="bibr" rid="ref16">16</xref>,<xref ref-type="bibr" rid="ref22">22</xref>,<xref ref-type="bibr" rid="ref23">23</xref></sup> Using the PBK modeling-based
QIVIVE approach, <italic toggle="yes">in vitro</italic> concentration-based toxic
effects can be converted to corresponding <italic toggle="yes">in vivo</italic> dose-dependent responses, supporting the derivation of PODs for
risk assessment without generating new animal data.<sup><xref ref-type="bibr" rid="ref16">16</xref>&#8722;<xref ref-type="bibr" rid="ref21">21</xref></sup></p><p>To predict acute toxicity following oral FNT administration
in
both rats and humans, the PBK modeling-facilitated QIVIVE approach
was employed in the present study. The rat and human PBK models for
FNT and its major metabolites were developed by integrating available
physiological parameters, and chemical-specific data that were obtained <italic toggle="yes">in silico</italic> and <italic toggle="yes">in vitro</italic>. Inhibition of erythrocyte
AChE in rat and human blood was determined <italic toggle="yes">in vitro</italic>. Then, the corresponding <italic toggle="yes">in vivo</italic> dose&#8211;response
relationships, obtained by converting <italic toggle="yes">in vitro</italic> AChE
inhibition data via QIVIVE, were used to perform a benchmark dose
(BMD) analysis to derive PODs for rats and humans. By comparing the
obtained PODs with available NOAELs,<sup><xref ref-type="bibr" rid="ref1">1</xref>,<xref ref-type="bibr" rid="ref11">11</xref>&#8722;<xref ref-type="bibr" rid="ref13">13</xref></sup> the performance of this approach was evaluated, and insights into
the potential interspecies susceptibility toward acute FNT toxicity
were provided.</p></sec><sec id="sec2"><label>2</label><title>Materials and Methods</title><sec id="sec2.1"><label>2.1</label><title><italic toggle="yes">In Vitro</italic> Incubations for
Deriving Kinetic Parameters</title><p><italic toggle="yes">In vitro</italic> incubations
were performed to obtain kinetic parameters for the CYP450s-catalyzed
conversion of FNT to FNO and MNP using gender-mixed rat and human
liver microsomes. For the PON1-dominated detoxification of FNO to
MNP, <italic toggle="yes">in vitro</italic> incubations were conducted with gender-mixed
liver microsomes or plasma from rats and humans. Sample extraction
with diisopropyl ether was performed before UPLC-PDA analysis. More
details on <italic toggle="yes">in vitro</italic> incubations, sample extraction,
UPLC-PDA analysis, and calculation of kinetic parameters are provided
in the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.est.3c07077/suppl_file/es3c07077_si_001.pdf">Supporting Information</ext-link>.</p></sec><sec id="sec2.2"><label>2.2</label><title><italic toggle="yes">In Vitro</italic> AChE Inhibition
Assay</title><p>Inhibition of rat and human erythrocyte AChE by FNT
and FNO was determined using rat and human blood. Additionally, <italic toggle="yes">in vitro</italic> AChE inhibition assay was also performed by exposing
recombinant human AChE and self-prepared rat erythrocyte AChE to FNT
and FNO in a low-protein medium to investigate the potential effect
induced by blood matrix. Details are provided in the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.est.3c07077/suppl_file/es3c07077_si_001.pdf">Supporting Information</ext-link>.</p></sec><sec id="sec2.3"><label>2.3</label><title>PBK Model
Establishment</title><p>The PBK model
for diazinon<sup><xref ref-type="bibr" rid="ref20">20</xref></sup> was used as a starting point
for establishing PBK models describing the toxicokinetics of FNT and
its major metabolites (FNO and MNP) in rats and humans. Side-products
DMTP and DMP formed during the conversion of FNT and of FNO to MNP,
respectively, are not explicitly included in the current models, as
they are not toxicologically relevant,<sup><xref ref-type="bibr" rid="ref24">24</xref></sup> and their exclusion will not affect the model performance. Adaptations
have been made to make the model more physiologically plausible by
adding a submodel to describe tissue distributions of MNP, and by
using glomerular filtration rate instead of fitted excretion rate
constant for urinary elimination. As presented in <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>, the model contains two submodels
for metabolites, and each (sub)model includes liver, kidney, blood,
fat, slowly perfused tissue, and rapidly perfused tissue compartments.
Species-specific physiological parameters are summarized in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.est.3c07077/suppl_file/es3c07077_si_001.pdf">Table S1</ext-link>. An oral exposure route was included
in the model considering that general populations are predominantly
exposed to FNT through food products and drinking water. An intravenous
(iv) route was also added into the model to enable the evaluation
of model performance by comparison to available kinetic data sets
in rats upon iv dosing.<sup><xref ref-type="bibr" rid="ref25">25</xref></sup></p><fig id="fig2" position="float" orientation="portrait"><label>Figure 2</label><caption><p>Schematic diagram of
the PBK model for FNT with submodels for its
major metabolites FNO and MNP.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gr2" position="float" orientation="portrait" xlink:href="es3c07077_0002.jpg"/></fig><p>The fraction of the dose absorbed (Fa) following oral exposure
to FNT was set at 0.9 for rats<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> and 0.7
for humans.<sup><xref ref-type="bibr" rid="ref2">2</xref></sup> A two-compartment gastrointestinal
tract model consisting of a stomach and an intestinal compartment
was used to describe oral absorption. Since absorption rate constants
for FNT were not available, the relevant constants for diazinon were
used considering that these two organophosphate pesticides have similar
lipophilicity<sup><xref ref-type="bibr" rid="ref26">26</xref></sup> and are both passively
absorbed. The rate constants describing the absorption from stomach
to liver (<italic toggle="yes">k</italic><sub>a</sub>S), absorption from intestine
to liver (<italic toggle="yes">k</italic><sub>a</sub>I), and transfer from stomach
to intestine (<italic toggle="yes">k</italic><sub>s</sub>I) were as follows: a <italic toggle="yes">k</italic><sub>a</sub>S of 0.1/h for rats and 0.32/h for humans,
along with a <italic toggle="yes">k</italic><sub>a</sub>I of 0.59/h and a <italic toggle="yes">k</italic><sub>s</sub>I of 0.48/h for both rats and humans.<sup><xref ref-type="bibr" rid="ref20">20</xref></sup></p><p>Distribution of FNT, FNO, and MNP across
tissues was described
by tissue:blood partition coefficients (<italic toggle="yes">P</italic>). The lipophilicity
(log <italic toggle="yes">P</italic>) and acid&#8211;base properties (p<italic toggle="yes">K</italic><sub>a</sub>) of these chemicals were precited using an
online platform MolGpKa,<sup><xref ref-type="bibr" rid="ref27">27</xref></sup> as relevant
experimental data are limited (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.est.3c07077/suppl_file/es3c07077_si_001.pdf">Table S2</ext-link>). Then, these predicted values were used as inputs for the online
QIVIVE tool (version 2.0)<sup><xref ref-type="bibr" rid="ref28">28</xref></sup> for predicting
the fraction unbound in plasma, and tissue:plasma partition coefficients.
Partition coefficients of FNT and FNO were predicted with the Berezhkovskiy
method.<sup><xref ref-type="bibr" rid="ref29">29</xref></sup> The Rodgers and Rowland method<sup><xref ref-type="bibr" rid="ref30">30</xref></sup> was chosen for MNP, given that it is ionized
in physiological conditions and this method takes into account the
impact of drug ionization on partitioning.<sup><xref ref-type="bibr" rid="ref31">31</xref></sup> The blood plasma ratio (BPr) was assumed to be 0.55 for neutral
(FNT and FNO) and acidic compounds (MNP), as suggested in the literature<sup><xref ref-type="bibr" rid="ref32">32</xref></sup> when experimental data are unavailable. Thus,
corresponding tissue:blood partition coefficients for FNT, FNO, and
MNP were obtained by dividing tissue:plasma partition coefficients
by the BPr to correct for the difference in compound distribution
between blood and plasma (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.est.3c07077/suppl_file/es3c07077_si_001.pdf">Table S1</ext-link>).</p><p>The CYP450s-catalyzed biotransformation of FNT was assumed to occur
only in the liver where these enzymes are predominantly expressed,<sup><xref ref-type="bibr" rid="ref33">33</xref></sup> and the resulting FNO and MNP were transferred
to the corresponding submodels. In the FNO submodel, the detoxification
of FNO to MNP by PON1 in both the liver and blood compartments was
incorporated, and the formed metabolite MNP was transferred to the
MNP submodel. Given that only the unbound fraction of chemicals is
assumed to be available for the biotransformation,<sup><xref ref-type="bibr" rid="ref34">34</xref></sup> unbound concentrations of FNT and FNO in liver and blood
were derived with unbound fraction factors as illustrated in the model
code (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.est.3c07077/suppl_file/es3c07077_si_001.pdf">Supporting Information</ext-link>). Kinetic
parameters related to bioactivation and detoxification were obtained
from <italic toggle="yes">in vitro</italic> incubations with liver microsomes or
plasma. The <italic toggle="yes">K</italic><sub>m</sub> determined <italic toggle="yes">in vitro</italic> was postulated to be equal to the <italic toggle="yes">K</italic><sub>m</sub><italic toggle="yes">in vivo</italic>. <italic toggle="yes">In vitro</italic><italic toggle="yes">V</italic><sub>max</sub> values were extrapolated to the corresponding <italic toggle="yes">in vivo</italic> values in liver, using liver microsomal protein
yield scaling factors of 35 and 32 mg microsomal protein/g liver for
rats and humans, respectively.<sup><xref ref-type="bibr" rid="ref35">35</xref>,<xref ref-type="bibr" rid="ref36">36</xref></sup> Plasma <italic toggle="yes">in vivo</italic><italic toggle="yes">V</italic><sub>max</sub> values were extrapolated from <italic toggle="yes">in vitro</italic><italic toggle="yes">V</italic><sub>max</sub> values with determined
plasma protein concentrations (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.est.3c07077/suppl_file/es3c07077_si_001.pdf">Supporting Information</ext-link>) for rats (59 mg of protein/mL) and humans (66 mg protein/mL). Intestinal
metabolism of FNT was not included in our model, given that its contribution
comparing to the total hepatic metabolism is probably negligible as
reported for chlorpyrifos and diazinon.<sup><xref ref-type="bibr" rid="ref20">20</xref>,<xref ref-type="bibr" rid="ref37">37</xref></sup></p><p>Urinary
elimination of FNT, FNO, and MNP from the systemic circulation
was described as the glomerular filtration rate times the venous blood
concentration leaving the kidney compartment. The glomerular filtration
rates in rats and humans used in the models were 5.2 and 1.8 mL/min/kg
BW, respectively.<sup><xref ref-type="bibr" rid="ref38">38</xref></sup></p><p>The model was
coded and employed with Berkeley Madonna (version
10.2.8, UC Berkeley, CA, USA), applying Rosenbrock&#8217;s algorithms
for stiff systems (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.est.3c07077/suppl_file/es3c07077_si_001.pdf">Supporting Information</ext-link>).</p></sec><sec id="sec2.4"><label>2.4</label><title>PBK Model Evaluation</title><p>To evaluate
the performance of the established rat and human PBK models, comparisons
were made between model predictions and reported <italic toggle="yes">in vivo</italic> rat and human kinetic data (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.est.3c07077/suppl_file/es3c07077_si_001.pdf">Table S3</ext-link>),
including time profiles of blood FNT concentrations and cumulative
urinary MNP excretion amounts upon oral or iv administrations. TechDig
2.0 was used to extract and convert graphic data from the reported <italic toggle="yes">in vivo</italic> studies to a numerical format.</p><p>A local sensitivity
analysis was performed to identify the influential parameters on the
maximum blood FNO concentration (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.est.3c07077/suppl_file/es3c07077_si_001.pdf">Supporting Information</ext-link>), as FNO is a more potent AChE inhibitor compared to its precursor
FNT, and its internal concentration is relevant for the toxicity prediction
following acute FNT exposure (see <xref rid="sec3.3" ref-type="other">section 3.3</xref>).</p></sec><sec id="sec2.5"><label>2.5</label><title>Model Application: QIVIVE</title><p>For toxicity
prediction, the maximum blood FNO concentration was used as a dose
metric relating AChE inhibition to acute FNT exposure (see <xref rid="sec3.3" ref-type="other">section 3.3</xref>). Since the <italic toggle="yes">in vitro</italic> AChE inhibition under increasing FNO concentrations was tested in
rat and human blood, these nominal concentrations could be used directly
as the biological effective concentrations (<italic toggle="yes">in vivo</italic> maximum blood FNO concentrations), and no extra correction for differences
in <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> protein
binding was deemed necessary. Then the corresponding FNT dose levels
resulting in these <italic toggle="yes">in vivo</italic> concentrations were derived
via PBK modeling-facilitated reverse dosimetry. In doing so, the <italic toggle="yes">in vitro</italic> concentration&#8211;response relationship was
converted to the predicted <italic toggle="yes">in vivo</italic> dose-dependent
erythrocyte AChE inhibition, which was then compared to available <italic toggle="yes">in vivo</italic> toxicity data in rats and humans.<sup><xref ref-type="bibr" rid="ref8">8</xref>,<xref ref-type="bibr" rid="ref39">39</xref></sup></p></sec><sec id="sec2.6"><label>2.6</label><title>BMD Analysis</title><p>BMD modeling was used
to derive POD values from the predicted <italic toggle="yes">in vivo</italic> dose-dependent
data sets for rats and humans. A BMD value resulting in a 10% benchmark
response (BMR) change with lower 95% confidence limit was defined
as BMDL<sub>10</sub>, and the obtained values for rats and humans
were evaluated against the reported NOAELs.<sup><xref ref-type="bibr" rid="ref1">1</xref>,<xref ref-type="bibr" rid="ref11">11</xref>&#8722;<xref ref-type="bibr" rid="ref13">13</xref></sup> Details and results of BMD analysis are provided
in the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.est.3c07077/suppl_file/es3c07077_si_001.pdf">Supporting Information</ext-link>.</p></sec></sec><sec id="sec3"><label>3</label><title>Results</title><sec id="sec3.1"><label>3.1</label><title><italic toggle="yes">In Vitro</italic> Kinetic Parameters</title><p>The biotransformation of FNT and FNO
was determined from <italic toggle="yes">in vitro</italic> incubations with gender-mixed
rat and human liver
microsomes or plasma. As shown in <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>, for rats and humans, FNT bioactivation
was faster than its detoxification and PON1-mediated FNO hydrolysis
was comparable in liver and plasma. Interspecies differences in toxicokinetics
were notable. The unscaled catalytic efficiency of the CYP450s-catalyzed
bioactivation was 6.4-fold higher in rats than in humans, though their
detoxification efficiencies were comparable (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.est.3c07077/suppl_file/es3c07077_si_001.pdf">Table S4</ext-link>). For the detoxification of FNO by liver and plasma PON1,
a faster hydrolysis was observed in rats than in humans (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>).</p><fig id="fig3" position="float" orientation="portrait"><label>Figure 3</label><caption><p><italic toggle="yes">In vitro</italic> CYP450s-mediated formation of (a) FNO
and (b) MNP in incubations with gender-mixed rat or human liver microsomes
upon increasing FNT concentrations. <italic toggle="yes">In vitro</italic> PON1-mediated
formation of MNP in incubations with (c) gender-mixed rat or human
liver microsomes and (d) gender-mixed rat or human plasma upon increasing
FNO concentrations. Results are presented as means &#177; SEM from
three independent experiments. The derived <italic toggle="yes">in vitro</italic> kinetic parameters (<italic toggle="yes">V</italic><sub>max</sub>, <italic toggle="yes">K</italic><sub>m</sub>, and catalytic efficiency) for rats and humans were
summarized in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.est.3c07077/suppl_file/es3c07077_si_001.pdf">Table S4</ext-link>. Due to solubility
limits, the highest FNO concentration tested was 5000 &#956;M. Although
curves in (c) and (d) did not reach plateaus, the correlation coefficient
(<italic toggle="yes">r</italic><sup>2</sup> &gt; 0.97) for the fit of the Michaelis&#8211;Menten
equation and the experimental data indicated an adequate fit of <italic toggle="yes">K</italic><sub>m</sub> and <italic toggle="yes">V</italic><sub>max</sub> values.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gr3" position="float" orientation="portrait" xlink:href="es3c07077_0003.jpg"/></fig></sec><sec id="sec3.2"><label>3.2</label><title>PBK Model Evaluation</title><p>The established
PBK models were first evaluated by comparing model predictions with
available <italic toggle="yes">in vivo</italic> kinetic data (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.est.3c07077/suppl_file/es3c07077_si_001.pdf">Table S3</ext-link>) to ensure their adequate performance. According
to the guideline<sup><xref ref-type="bibr" rid="ref40">40</xref></sup> from the World Health
Organization, model predictions that are within 2-fold difference
as compared to the experimental data are considered to be well-fitted,
while a larger difference is also acceptable especially when experimental
data sets obtained from different studies show inconsistencies.</p><p>For the rat model, time-based rat blood FNT concentrations following
oral FNT administration were available.<sup><xref ref-type="bibr" rid="ref41">41</xref>,<xref ref-type="bibr" rid="ref42">42</xref></sup> Interestingly,
potential gender-related differences in rats were noticed,<sup><xref ref-type="bibr" rid="ref41">41</xref></sup> where at the same dose level and time point,
blood FNT concentrations in female rats were higher than those in
males, and also reached the peak concentration within a shorter period
(<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>a). In addition,
variations between <italic toggle="yes">in vivo</italic> studies<sup><xref ref-type="bibr" rid="ref41">41</xref>,<xref ref-type="bibr" rid="ref42">42</xref></sup> were observed, where the disappearance of FNT in blood differed,
though in both studies the male rats were exposed to the same dose
(<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>a). Our predicted
blood FNT concentrations from the gender-mixed model fit well with
the averaged data of male and female rats (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>a). The model overpredicted the concentrations
collected solely from males (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>a,b), probably due to gender-related differences. In
another <italic toggle="yes">in vivo</italic> study,<sup><xref ref-type="bibr" rid="ref25">25</xref></sup> cumulative urinary MNP excretion was monitored in female rats after
oral or iv administration of FNT. Our predicted MNP excretion matched
the respective experimental data well, and the differences were within
2.0 and 1.5-fold, respectively (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>c,d).</p><fig id="fig4" position="float" orientation="portrait"><label>Figure 4</label><caption><p>Comparisons between reported <italic toggle="yes">in vivo</italic> rat
data
and predictions made from the gender-mixed rat PBK model. Predicted
and reported (a) time-dependent blood FNT concentrations in male and
female rats upon single oral administration of FNT at 15 mg/kg BW;<sup><xref ref-type="bibr" rid="ref41">41</xref>,<xref ref-type="bibr" rid="ref42">42</xref></sup> (b) time-dependent blood FNT concentrations in male rats upon single
oral administration of FNT at 50 mg/kg BW;<sup><xref ref-type="bibr" rid="ref42">42</xref></sup> (c) time-dependent cumulative urinary MNP excretion in female rats
upon single oral administration of FNT at 47 mg/kg BW;<sup><xref ref-type="bibr" rid="ref25">25</xref></sup> and (d) time-dependent cumulative urinary MNP
excretion in female rats upon iv administration of FNT at 0.94 mg/kg
BW.<sup><xref ref-type="bibr" rid="ref25">25</xref></sup></p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gr4" position="float" orientation="portrait" xlink:href="es3c07077_0004.jpg"/></fig><p>For the human model, time profiles of blood FNT concentrations
and urinary MNP amounts following a single oral administration of
FNT were available. In a volunteer study,<sup><xref ref-type="bibr" rid="ref43">43</xref></sup> 12 participants (8 males and 4 females) received FNT formulated
as a capsule together with food for 4 days, with the daily dose being
administrated as two divided doses with a 12 h interval. The time-based
blood FNT concentrations within the first 12 h following a single
FNT exposure were collected, and large interindividual variations
were noted (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>a,b). The differences between the averaged <italic toggle="yes">in vivo</italic> data and model predictions were within 1.7 and 2.2-fold at dose
levels of 0.09 and 0.18 mg/kg BW, respectively (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>a,b). In another volunteer study,<sup><xref ref-type="bibr" rid="ref39">39</xref></sup> FNT was prepared with olive oil in gelatin capsules
and was given to 24 individuals (gender unspecified), and the administrated
doses (0.042, 0.083, 0.17, 0.25, and 0.33 mg/kg BW) were calculated
with an average body weight of 60 kg as used by JMPR<sup><xref ref-type="bibr" rid="ref2">2</xref></sup> and APVMA.<sup><xref ref-type="bibr" rid="ref12">12</xref></sup> The cumulative
urinary MNP excretion within 24 h following these five dose levels
was reported, and the differences between the reported average values
and our predictions were within 2.0-fold (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>c).</p><fig id="fig5" position="float" orientation="portrait"><label>Figure 5</label><caption><p>Comparisons between human PBK model predictions
and reported <italic toggle="yes">in vivo</italic> human data. Predicted and reported
(a) time-dependent
blood FNT concentrations in humans upon single oral administration
of FNT at 0.09 mg/kg BW;<sup><xref ref-type="bibr" rid="ref43">43</xref></sup> (b) time-dependent
blood FNT concentrations in humans upon single oral administration
of FNT at 0.18 mg/kg BW;<sup><xref ref-type="bibr" rid="ref43">43</xref></sup> and (c) dose-dependent
cumulative urinary MNP excretion within 24 h in humans upon single
oral administration of FNT at 0.042, 0.083, 0.17, 0.25, and 0.33 mg/kg
BW.<sup><xref ref-type="bibr" rid="ref39">39</xref></sup> Data collected from the literature
are presented as means &#177; SEM (where available).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gr5" position="float" orientation="portrait" xlink:href="es3c07077_0005.jpg"/></fig><p>Taking all comparisons into consideration, we concluded that
the
rat and human PBK models were able to provide adequate predictions
of time-dependent blood FNT concentrations and urinary MNP amounts.
Following a local sensitivity analysis to have an overview of the
influential parameters on the model output (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.est.3c07077/suppl_file/es3c07077_si_001.pdf">Figure S1</ext-link>), the rat and human PBK models were subsequently used for
QIVIVE.</p></sec><sec id="sec3.3"><label>3.3</label><title>Prediction and Evaluation of <italic toggle="yes">In Vivo</italic> Dose-Dependent AChE Inhibition</title><p>The <italic toggle="yes">in vitro</italic> concentration-dependent AChE inhibition in blood under increasing
concentrations of FNT and FNO was determined for rats and humans.
As shown in <xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig">6</xref></xref>, FNT is corroborated to be a weak AChE inhibitor, with a concentration
resulting in 50% inhibition (IC<sub>50</sub>) of about 500 &#956;M
for rats and an IC<sub>50</sub> greater than the highest tested concentration
(500 &#956;M) for humans. FNO is a more potent inhibitor as compared
with its precursor FNT, and comparable IC<sub>50</sub> values of FNO
were obtained for rats (0.95 &#956;M) and humans (0.84 &#956;M).
Given that FNO could induce inhibition to rat and human erythrocyte
AChE at a much lower concentration than FNT (<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig">6</xref></xref>), and that its blood concentration is predicted
to be higher than that of FNT in both rats and humans at an FNT dose
range relevant for risk assessment (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.est.3c07077/suppl_file/es3c07077_si_001.pdf">Figure S2</ext-link>), it can be concluded that the contribution of FNT to AChE inhibition
is negligible. Therefore, the maximum FNO concentration in blood is
relevant for the acute toxicity following FNT exposure and was used
for subsequent QIVIVE.</p><fig id="fig6" position="float" orientation="portrait"><label>Figure 6</label><caption><p>Blood AChE activity upon incubation with increasing concentrations
of FNT and FNO in (a) rats and (b) humans. Results are presented as
means &#177; SEM from three independent experiments. The background
AChE activities in rat and human blood without exposure to compounds
and solvent were 0.5 and 4.1 U/mL, respectively.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gr6" position="float" orientation="portrait" xlink:href="es3c07077_0006.jpg"/></fig><p>The <italic toggle="yes">in vitro</italic> FNO concentration-based AChE inhibition
obtained using rat and human blood were converted to corresponding <italic toggle="yes">in vivo</italic> FNT dose-dependent response curves via PBK modeling-facilitated
QIVIVE and then compared to available <italic toggle="yes">in vivo</italic> AChE
inhibition data (<xref rid="fig7" ref-type="fig">Figure <xref rid="fig7" ref-type="fig">7</xref></xref>). For rats, the erythrocyte AChE activity was measured 2 h after
oral administration of FNT at dose levels of 2.5, 5, 7.5, 10, and
25 mg/kg BW in males,<sup><xref ref-type="bibr" rid="ref8">8</xref></sup> and its activity
decreased rapidly with increasing FNT dose levels (<xref rid="fig7" ref-type="fig">Figure <xref rid="fig7" ref-type="fig">7</xref></xref>a). Our predictions are comparable
with the <italic toggle="yes">in vivo</italic> data and describe the fast dropping
of AChE activity well (<xref rid="fig7" ref-type="fig">Figure <xref rid="fig7" ref-type="fig">7</xref></xref>a). One human study<sup><xref ref-type="bibr" rid="ref39">39</xref></sup> reporting
AChE inhibition following a single FNT administration was found, where
relatively low dose levels (0.042, 0.083, 0.17, 0.25, and 0.33 mg/kg
BW) were orally administered to 24 participants (gender unspecified),
and the erythrocyte AChE activity was monitored at 6 and 24 h after
exposure. The predicted curve for humans confirms that at the dose
levels reported in the study the AChE inhibition is indeed limited
(<xref rid="fig7" ref-type="fig">Figure <xref rid="fig7" ref-type="fig">7</xref></xref>b).</p><fig id="fig7" position="float" orientation="portrait"><label>Figure 7</label><caption><p>Predicted <italic toggle="yes">in vivo</italic> dose-dependent AChE activity
by PBK modeling-facilitated QIVIVE for (a) rats and (b) humans upon
a single oral administration of FNT. Available <italic toggle="yes">in vivo</italic> erythrocyte AChE inhibition data in male rats<sup><xref ref-type="bibr" rid="ref8">8</xref></sup> and humans<sup><xref ref-type="bibr" rid="ref39">39</xref></sup> are presented as
means &#177; SEM (where available). Reported NOAELs<sup><xref ref-type="bibr" rid="ref1">1</xref>,<xref ref-type="bibr" rid="ref11">11</xref>&#8722;<xref ref-type="bibr" rid="ref13">13</xref></sup> for rats and humans are plotted as black square or
diamond by assuming that these values represented the dose levels
that resulted in 10% inhibition in AChE activity.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gr7" position="float" orientation="portrait" xlink:href="es3c07077_0007.jpg"/></fig></sec><sec id="sec3.4"><label>3.4</label><title>POD Derivation and Evaluation</title><p>By
performing BMD analysis on the predicted rat and human <italic toggle="yes">in
vivo</italic> dose-dependent erythrocyte AChE inhibition curves, a
rat and a human BMDL<sub>10</sub> were derived as PODs. The results
(<xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>) indicate
that the predicted POD for humans is 5-fold lower than that of rats,
suggesting that humans are more susceptible than rats toward the acute
toxicity induced by FNT.</p><table-wrap id="tbl1" position="float" orientation="portrait"><label>Table 1</label><caption><title>Comparisons of Reported
NOAEL and
Predicted BMDL<sub>10</sub> Values</title></caption><table frame="hsides" rules="groups" border="0"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th rowspan="2" style="border:none;" align="left" colspan="1"><bold>POD
(mg/kg BW)</bold></th><th colspan="2" align="center" rowspan="1"><bold>reported NOAEL</bold><hr/></th><th colspan="2" align="center" rowspan="1"><bold>predicted
BMDL<sub>10</sub></bold><hr/></th></tr><tr><th style="border:none;" align="center" colspan="1" rowspan="1">rat</th><th style="border:none;" align="center" colspan="1" rowspan="1">human</th><th style="border:none;" align="center" colspan="1" rowspan="1">rat</th><th style="border:none;" align="center" colspan="1" rowspan="1">human</th></tr></thead><tbody><tr><td style="border:none;" align="left" colspan="1" rowspan="1"><bold>FNT</bold></td><td style="border:none;" align="center" colspan="1" rowspan="1">0.25 (US EPA); 1.30 (EFSA)</td><td style="border:none;" align="center" colspan="1" rowspan="1">0.33 (APVMA); 0.36 (JMPR)</td><td style="border:none;" align="center" colspan="1" rowspan="1">1.30</td><td style="border:none;" align="center" colspan="1" rowspan="1">0.26</td></tr></tbody></table></table-wrap><p>Different NOAELs used by several organizations
for setting ARfDs
are summarized in <xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>. A NOAEL of 1.3 mg/kg BW was reported by EFSA<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> from a 90 day rat study<sup><xref ref-type="bibr" rid="ref44">44</xref></sup> considering
the impaired body weight gain and reduction in erythrocyte and brain
cholinesterase activity as the critical effects. The US EPA<sup><xref ref-type="bibr" rid="ref11">11</xref></sup> reported a 5.2-fold lower NOAEL (0.25 mg/kg
BW) based on the measured erythrocyte AChE inhibition after 2 weeks
of FNT dosing in a 92 week rat study.<sup><xref ref-type="bibr" rid="ref45">45</xref></sup> Different from EFSA and the US EPA, APVMA and JMPR derived NOAELs
based on available human data. APVMA<sup><xref ref-type="bibr" rid="ref12">12</xref></sup> established
a NOAEL of 0.33 mg/kg BW from a single dose human study,<sup><xref ref-type="bibr" rid="ref39">39</xref></sup> based on the absence of any inhibition of plasma
and erythrocyte cholinesterase activity at this highest dose level
tested in human volunteers. JMPR<sup><xref ref-type="bibr" rid="ref13">13</xref></sup> identified
a 4 day study in human volunteers<sup><xref ref-type="bibr" rid="ref43">43</xref></sup> as
the most suitable study, and set a NOAEL of 0.36 mg/kg BW where no
subject showed decreases in erythrocyte AChE activity at this highest
dose level tested. Our predicted POD for rats is comparable to the
NOAEL derived by EFSA, and the predicted POD for humans is in line
with the current human NOAELs (<xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>).</p></sec></sec><sec id="sec4"><label>4</label><title>Discussion</title><p>This
work aimed to use an approach in accordance with the 3R principles
(Replacement, Reduction, and Refinement) of animal testing to predict
dose levels at which humans would not be at risk for acute neurotoxicity
due to erythrocyte AChE inhibition induced by an oral exposure to
FNT. To this end, PBK models for both rats and humans were first established
and validated. Subsequently, the models were used for QIVIVE to convert
the <italic toggle="yes">in vitro</italic> determined concentration-dependent AChE
inhibition in rat and human blood to <italic toggle="yes">in vivo</italic> dose-dependent
curves, from which rat and human BMDL<sub>10</sub> values were derived
as PODs, which were comparable with the current rat and human NOAELs.</p><p>Following exposure to organophosphate pesticides, liver CYP450s-mediated
bioactivation and detoxification take place.<sup><xref ref-type="bibr" rid="ref46">46</xref></sup> For FNT, the bioactivation instead of its detoxification is found
to be more efficient in rats and humans (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>), as opposed to the results found for chlorpyrifos
and diazinon.<sup><xref ref-type="bibr" rid="ref18">18</xref>,<xref ref-type="bibr" rid="ref20">20</xref></sup> Several CYP450s including 1A2,
2B6, 2C19, and 3A4 were reported to participate in both bioactivation
and detoxification of organophosphate pesticides,<sup><xref ref-type="bibr" rid="ref19">19</xref>,<xref ref-type="bibr" rid="ref20">20</xref></sup> while specific information on the CYP450s involved in FNT metabolism
is limited. Levi et al.<sup><xref ref-type="bibr" rid="ref47">47</xref></sup> purified two
chemically induced isoforms (named as P-450 PB and P-450 BNF) from
livers of mice that were pretreated orally or intraperitoneally with
phenobarbital (PB) or &#946;-naphthoflavone (BNF), inducers for CYP2B9/10
and 1A1/2 in mice, respectively.<sup><xref ref-type="bibr" rid="ref48">48</xref>,<xref ref-type="bibr" rid="ref49">49</xref></sup> In their study,
P-450 PB and P-450 BNF were reported to produce higher amounts of
FNO compared to MNP production. Given that CYP1A and 2B genes presumably
carry out similar or identical functions in both humans and mice,<sup><xref ref-type="bibr" rid="ref50">50</xref></sup> CYP1A2 and 2B6 in humans are speculated to mainly
participate in the bioactivation of FNT. This assumption is in line
with the observations from a study,<sup><xref ref-type="bibr" rid="ref51">51</xref></sup> where
methyl parathion, a structural analog of FNT (methyl parathion lacks
a methyl group on the aryl group) was incubated with several recombinant
human CYP450s, and 1A2 and 2B6 were found to mainly participate in
its bioactivation. Additionally, CYP2D6 might also participate in
the FNT biotransformation, given that the classical substrates for
CYP2D6 are aryl- or alkyl-amines with ionized nitrogen at physiological
conditions.<sup><xref ref-type="bibr" rid="ref52">52</xref></sup> Due to the varied expression
and activity of the CYP450s<sup><xref ref-type="bibr" rid="ref33">33</xref></sup> that might
participate in the bioactivation and detoxification of FNT, toxicokinetic
differences among individuals could be expected, which might be an
explanation to the interindividual variances reported in the blood
FNT concentrations under the same exposure level.<sup><xref ref-type="bibr" rid="ref43">43</xref></sup></p><p>PON1 is primarily synthesized in the liver and secreted
into the
blood,<sup><xref ref-type="bibr" rid="ref53">53</xref></sup> it is active as a main esterase
in hydrolyzing oxon analogues rather than the thiophosphate precursors
like FNT in this study.<sup><xref ref-type="bibr" rid="ref46">46</xref></sup> Hydrolysis efficiency
of PON1 toward oxons varies among organophosphate pesticides, as a
slight change in their leaving groups can affect the orientation of
the oxon in the active site and hence their conversion.<sup><xref ref-type="bibr" rid="ref54">54</xref></sup> For example, the PON1-catalyzed detoxification
of methyl paraoxon was found to be less efficient than that of CPO
in both rats and humans.<sup><xref ref-type="bibr" rid="ref54">54</xref>,<xref ref-type="bibr" rid="ref55">55</xref></sup> This observation is
in agreement with the lower PON1 catalytic efficiency toward FNO (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.est.3c07077/suppl_file/es3c07077_si_001.pdf">Table S4</ext-link>) as compared to that of CPO,<sup><xref ref-type="bibr" rid="ref19">19</xref></sup> considering that methyl paraoxon and FNO are
highly similar in structure. Similar to CYP450s, the activity of PON1
shows interindividual differences,<sup><xref ref-type="bibr" rid="ref56">56</xref></sup> while
relevant information is limited on how it will affect the resulting
toxicity among individuals following acute FNT exposure.</p><p>In
addition to liver and plasma clearance, renal clearance of FNT,
FNO, and MNP was also included in the established PBK models. Currently,
glomerular filtration is considered as the major elimination route.
MNP can be cleared renally by glomerular filtration;<sup><xref ref-type="bibr" rid="ref57">57</xref></sup> however, the use of glomerular filtration for FNT and FNO
might overestimate their renal clearance to some extent, as passive
reabsorption might occur for chemicals with high lipophilicity.<sup><xref ref-type="bibr" rid="ref57">57</xref></sup> This might be an explanation for the underestimation
of urinary MNP excretion in humans (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>c), as the formation of MNP from FNT and
FNO might be underestimated due to the probable overestimation of
the elimination of FNT and FNO in urine. Further studies are necessary
to enable refinement of the modeling to renal elimination of organophosphate
pesticides.</p><p>AChE is encoded by a single gene.<sup><xref ref-type="bibr" rid="ref58">58</xref></sup> In
addition to neuromuscular junctions, AChE is also present in the blood
(erythrocyte AChE), though its physiological function to the erythrocytes
is still unclear.<sup><xref ref-type="bibr" rid="ref59">59</xref></sup> The mechanism of acute
neurotoxicity following organophosphate pesticide exposures is the
inhibition of neuronal AChE; however, relevant <italic toggle="yes">in vivo</italic> data for it are usually unavailable especially for humans. In the
absence of this information, the inhibition of erythrocyte AChE is
considered to be an acceptable surrogate endpoint in scientific studies<sup><xref ref-type="bibr" rid="ref18">18</xref>&#8722;<xref ref-type="bibr" rid="ref21">21</xref></sup> and by regulatory bodies<sup><xref ref-type="bibr" rid="ref60">60</xref></sup> because erythrocyte
AChE is more sensitive than the neuronal AChE,<sup><xref ref-type="bibr" rid="ref61">61</xref></sup> suggesting that a conservative POD could be derived with
this endpoint.</p><p>FNO shows a similar inhibition potency toward
erythrocyte AChE
in rats and humans, while the contribution of FNT to AChE inhibition
is negligible (<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig">6</xref></xref>). Interestingly, the activity of self-prepared rat erythrocyte AChE
and recombinant human AChE is notably inhibited by both FNT and FNO
(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.est.3c07077/suppl_file/es3c07077_si_001.pdf">Figure S3</ext-link>), and the obtained IC<sub>50</sub> values for FNO are 5.3 and 3.4-fold lower than those obtained in
rat and human blood, respectively. Similar observations are also noted
for diazinon and its oxon, where diazinon inhibited AChE activity
when measuring with recombinant human AChE in a low-protein medium,<sup><xref ref-type="bibr" rid="ref20">20</xref></sup> but exerted a limited influence on AChE inhibition
when measuring with human blood.<sup><xref ref-type="bibr" rid="ref62">62</xref></sup> As for
diazinon oxon, a lower IC<sub>50</sub> was derived with the recombinant
enzyme<sup><xref ref-type="bibr" rid="ref20">20</xref></sup> than that obtained with blood.<sup><xref ref-type="bibr" rid="ref62">62</xref></sup> These observations indicate that specific factor(s)
(i.e., plasma proteins) present in the blood might affect the interaction
between AChE and organophosphate pesticides. The AChE inhibition data
obtained from rat and human blood were used for QIVIVE in the present
study, as testing with blood could simulate the physiological conditions
better, and also takes into account the potential differences induced
by species-dependent blood matrix effects (<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig">6</xref></xref>).</p><p>Species-relevant toxicokinetic differences
were observed in the
current study, where rats appeared to be more efficient in FNT and
FNO conversion than humans (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>). Interestingly, when exposed to the same dose levels,
comparable maximum blood FNO concentrations were predicted for the
two species (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.est.3c07077/suppl_file/es3c07077_si_001.pdf">Figure S2</ext-link>), indicating that
there are other reasons that cause different POD predictions for rats
and humans. Though similar IC<sub>50</sub> values for FNO toward rat
and human erythrocyte AChE activity are derived, the rat and human <italic toggle="yes">in vitro</italic> AChE inhibition curves especially in the low-concentration
region are different. Specifically, in the <italic toggle="yes">in vitro</italic> assay, the AChE activity in rat blood is initially resistant to
increasing FNO concentrations before a fast dropping, while the human
AChE activity decreases progressively in the whole FNO concentration
range (<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig">6</xref></xref>). After
conversion to the <italic toggle="yes">in vivo</italic> dose&#8211;response curve
(<xref rid="fig7" ref-type="fig">Figure <xref rid="fig7" ref-type="fig">7</xref></xref>) for BMD
analysis, the low-dose region becomes particular important as this
is the region for POD (BMDL<sub>10</sub>) derivation.<sup><xref ref-type="bibr" rid="ref63">63</xref></sup> Plasma carboxylesterase might be a factor related to the
low-dose differences observed between rat and human blood, as this
enzyme could protect AChE by scavenging oxon analogues of organophosphate
pesticides,<sup><xref ref-type="bibr" rid="ref64">64</xref></sup> while human plasma contains
no carboxylesterase as opposed to the rat plasma.<sup><xref ref-type="bibr" rid="ref65">65</xref></sup></p><p>Additionally, gender-related differences were noticed
between male
and female rats. Compared to males, female rats have a slower FNT
biotransformation at the same exposure level.<sup><xref ref-type="bibr" rid="ref41">41</xref></sup> However, further information on the resulting maximum blood FNO
concentration is limited. For humans, relevant information about gender-dependent
FNT depletion and FNO formation is unavailable. More studies are necessary
to clarify the relationship, if it exists, between gender-related
expression of specific enzymes and the resulting toxicity.</p><p>Still,
further work could be made to improve the current approach
by taking into consideration the following limitations. First, only
FNO and MNP as major metabolites of FNT were included in the biotransformation
(<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>), while other
metabolites might also be formed. For example, demethyl-FNT and demethyl-FNO
were detected in the urine during 48 h after an oral administration
of FNT (15 mg/kg BW) in rats, mice, rabbits, and dogs, and their relative
amounts were species-specific.<sup><xref ref-type="bibr" rid="ref41">41</xref></sup> No relevant
information for humans is available. Interestingly, demethyl-FNT and
demethyl-FNO were not found in our <italic toggle="yes">in vitro</italic> incubations
with rat or human liver microsomes, indicating that their formation,
at least <italic toggle="yes">in vitro</italic>, is inefficient compared to the
formation of FNO and MNP. Second, the MNP submodel included in our
current PBK models only describes its tissue distribution and urinary
excretion, without capturing its further glucuronidation and sulfation
in the liver.<sup><xref ref-type="bibr" rid="ref41">41</xref>,<xref ref-type="bibr" rid="ref42">42</xref></sup> This is because the data sets
used for model validation (<xref rid="fig4" ref-type="fig">Figures <xref rid="fig4" ref-type="fig">4</xref></xref>c,d and <xref rid="fig5" ref-type="fig">5</xref>c) provided the total
amount of MNP cumulated in the urine, of which the conjugated MNP
was released by acidic hydrolysis during sample preparation.<sup><xref ref-type="bibr" rid="ref66">66</xref>,<xref ref-type="bibr" rid="ref67">67</xref></sup> Third, ethopropazine was used as an inhibitor to butyrylcholinesterase
in the <italic toggle="yes">in vitro</italic> AChE inhibition assay<sup><xref ref-type="bibr" rid="ref62">62</xref></sup> and this might result in a conservative POD
prediction, as butyrylcholinesterase could protect erythrocyte AChE
by binding with oxon analogues of organophosphate pesticides.<sup><xref ref-type="bibr" rid="ref68">68</xref></sup> The potential protection from butyrylcholinesterase
especially for humans, who have a much higher plasma butyrylcholinesterase
activity than rats,<sup><xref ref-type="bibr" rid="ref69">69</xref>,<xref ref-type="bibr" rid="ref70">70</xref></sup> was not taken into account, and
this might explain the gap between the predicted and reported PODs
for humans (<xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>). Fourth, a common challenge exists when extrapolating from an <italic toggle="yes">in vitro</italic> endpoint to an <italic toggle="yes">in vivo</italic> apical
endpoint that usually occurs on a different time scale, due to, i.e.,
time for toxicokinetics <italic toggle="yes">in vivo</italic>.<sup><xref ref-type="bibr" rid="ref71">71</xref></sup> In the future, the current model could be refined by combining
it with a dynamic (D) submodel with parameters describing synthesis,
degradation, inhibition, reactivation, and aging of AChE. Relevant
PBK/D models have been developed for chlorpyrifos and diazinon.<sup><xref ref-type="bibr" rid="ref72">72</xref>,<xref ref-type="bibr" rid="ref73">73</xref></sup> In this way, the time-dependent relationship between oxon concentrations
in target tissues and the resulting AChE inhibition could be correlated.
In spite of these limitations, the current approach could adequately
predict toxicokinetics (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref> and <xref rid="fig5" ref-type="fig">5</xref>) and PODs (<xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>), suggesting that it is sufficient
for hazard and risk assessment upon acute FNT exposure.</p><p>In summary,
the results obtained in the current study provide a
proof-of-principle for applying the PBK modeling facilitated-QIVIVE
approach for predicting erythrocyte AChE inhibition induced by acute
FNT exposure. This approach can be applied for other organophosphate
pesticides by modifying the chemical-specific parameters used in the
PBK model and QIVIVE. Considering that organophosphate pesticides
will still be used worldwide for a long time, this approach is promising
in deriving PODs for the risk and safety evaluation of organophosphate
pesticides in accordance with the 3R principles, and could also facilitate
the future development of a generic PBK model to predict the acute
toxicity for a large number of organophosphate pesticides.</p></sec></body><back><notes id="notes1" notes-type="si"><title>Supporting Information Available</title><p>The Supporting Information
is
available free of charge at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/10.1021/acs.est.3c07077?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.est.3c07077</ext-link>.<list list-type="simple"><list-item><p>Materials and methods for <italic toggle="yes">in vitro</italic> incubations,
sample extraction, UPLC-PDA analysis, plasma protein concentration
determination, and <italic toggle="yes">in vitro</italic> AChE inhibition assay;
local sensitivity analysis; summary of physiological, physicochemical
and kinetic parameters; summary of available <italic toggle="yes">in vivo</italic> kinetic studies in rats and humans; summary of log <italic toggle="yes">P</italic> and p<italic toggle="yes">K</italic><sub>a</sub> values; details of BMD analysis;
PBK model codes (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.est.3c07077/suppl_file/es3c07077_si_001.pdf">PDF</ext-link>)</p></list-item></list></p></notes><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="sifile1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="es3c07077_si_001.pdf" position="float" orientation="portrait"><caption><p>es3c07077_si_001.pdf</p></caption></media></supplementary-material></sec><notes notes-type="" id="notes2"><title>Author Present Address</title><p><sup>#</sup> S.Z.: The Procter &amp; Gamble Company, Beijing,
101318, People&#8217;s
Republic of China. Work done prior to joining The Procter &amp; Gamble
Company</p></notes><notes notes-type="COI-statement" id="NOTES-d14e1166-autogenerated"><p>The
authors declare no
competing financial interest.</p></notes><ack><title>Acknowledgments</title><p>This work was funded by a grant from
the China Scholarship
Council (no. 202009370057 to J.C.). Through the contribution of N.I.K.,
I.M.C.M.R., and H.B. to this work, this work was cofunded by the European
Union through Horizon Europe project &#8220;European Partnership
for the Assessment of Risk from Chemicals (PARC)&#8221; under a grant
agreement no. 101057014. This publication reflects only the authors&#8217;
view and does not necessarily reflect those of the funding bodies.
The European Union is not responsible for any use that may be made
of the information it contains. The graphic for Table of Contents
was created with <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://BioRender.com">BioRender.com</uri>.</p></ack><ref-list><title>References</title><ref id="ref1"><mixed-citation publication-type="undeclared" id="cit1">European
Food Safety Authority. <article-title>Conclusion regarding the peer
review of the pesticide risk assessment
of the active substance fenitrothion</article-title>. <source>EFSA
J.</source><year>2006</year>, <volume>4</volume>( (<issue>2</issue>), ), <fpage>59r</fpage>.<pub-id pub-id-type="doi">10.2903/j.efsa.2006.59r</pub-id>; <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://efsa.onlinelibrary.wiley.com/doi/epdf/10.2903/j.efsa.2006.59r">https://efsa.onlinelibrary.wiley.com/doi/epdf/10.2903/j.efsa.2006.59r</uri>.<pub-id pub-id-type="pmcid">PMC10193659</pub-id><pub-id pub-id-type="pmid">37213826</pub-id></mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="undeclared" id="cit2"><source>Pesticide
residues in food
2000: Joint FAO/WHO Meeting on Pesticide Residues; Report</source>; <publisher-name>Food and Agriculture Organization of the United
Nations/World Health Organization</publisher-name>: <publisher-loc>Rome, Italy</publisher-loc>, <year>2001</year>; <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fao.org/3/cb2757en/cb2757en.pdf">https://www.fao.org/3/cb2757en/cb2757en.pdf</uri>.</mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="book" id="cit3"><person-group person-group-type="allauthors"><name name-style="western"><surname>Bele&#241;o</surname><given-names>M. T.</given-names></name>; <name name-style="western"><surname>Stoytcheva</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Zlatev</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Montero</surname><given-names>G.</given-names></name></person-group><article-title>Fenitrothion:
structural features, applications, toxicity mechanisms and effects
of exposure on human health &#8211; A review</article-title>. In <source>Organophosphorus Pesticides: Structural Characteristics, Mechanisms
of Toxicity and Effects of Exposure on Health</source>; <person-group person-group-type="editor"><name name-style="western"><surname>Wilkinson</surname><given-names>N.</given-names></name></person-group>, Eds.; <publisher-name>Nova Science
Publisher Inc.</publisher-name>: <publisher-loc>New York</publisher-loc>, <year>2016</year>; pp <fpage>91</fpage>.</mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal" id="cit4"><name name-style="western"><surname>Medina-Pastor</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Triacchini</surname><given-names>G.</given-names></name><article-title>The 2018 European Union report on pesticide residues
in food</article-title>. <source>EFSA J.</source><year>2020</year>, <volume>18</volume> (<issue>4</issue>), <fpage>1</fpage>&#8211;<lpage>103</lpage>. <pub-id pub-id-type="doi">10.2903/j.efsa.2020.6057</pub-id>.<pub-id pub-id-type="pmcid">PMC7447915</pub-id><pub-id pub-id-type="pmid">32874271</pub-id></mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="journal" id="cit5"><name name-style="western"><surname>Triassi</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Nardone</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Giovinetti</surname><given-names>M. C.</given-names></name>; <name name-style="western"><surname>De Rosa</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Canzanella</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Sarnacchiaro</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Montuori</surname><given-names>P.</given-names></name><article-title>Ecological risk and estimates of
organophosphate pesticides loads into the Central Mediterranean Sea
from Volturno River, the river of the &#8243;Land of Fires&#8243;
area, southern Italy</article-title>. <source>Sci. Total Environ.</source><year>2019</year>, <volume>678</volume>, <fpage>741</fpage>&#8211;<lpage>754</lpage>. <pub-id pub-id-type="doi">10.1016/j.scitotenv.2019.04.202</pub-id>.<pub-id pub-id-type="pmid">31082780</pub-id></mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="journal" id="cit6"><name name-style="western"><surname>Merga</surname><given-names>L. B.</given-names></name>; <name name-style="western"><surname>Mengistie</surname><given-names>A. A.</given-names></name>; <name name-style="western"><surname>Alemu</surname><given-names>M. T.</given-names></name>; <name name-style="western"><surname>van den Brink</surname><given-names>P. J.</given-names></name><article-title>Biological
and chemical monitoring of the ecological risks of pesticides in Lake
Ziway, Ethiopia</article-title>. <source>Chemosphere.</source><year>2021</year>, <volume>266</volume>, <elocation-id>129214</elocation-id><pub-id pub-id-type="doi">10.1016/j.chemosphere.2020.129214</pub-id>.<pub-id pub-id-type="pmid">33310518</pub-id></mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="undeclared" id="cit7"><source>Fenitrothion
in drinking-water:
Background document for development of WHO guidelines for drinking-water
quality</source>. <publisher-name>World Health Organization</publisher-name>: <publisher-loc>Geneva, Switzerland</publisher-loc>, <year>2004</year>; <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://cdn.who.int/media/docs/default-source/wash-documents/wash-chemicals/fenitrothion-bd.pdf?sfvrsn=c8504e7c_4">https://cdn.who.int/media/docs/default-source/wash-documents/wash-chemicals/fenitrothion-bd.pdf?sfvrsn=c8504e7c_4</uri>.</mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="journal" id="cit8"><name name-style="western"><surname>Miyamoto</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Sato</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Kadota</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Fujinami</surname><given-names>A.</given-names></name><article-title>Studies on the mode
of action of organophosphorus compounds: Part II Inhibition of mammalian
cholinesterase <italic toggle="yes">in vivo</italic> following the administration
of sumithion and methylparathion</article-title>. <source>Agric. biol.
Chem.</source><year>1963</year>, <volume>27</volume>, <fpage>669</fpage>&#8211;<lpage>676</lpage>. <pub-id pub-id-type="doi">10.1080/00021369.1963.10858170</pub-id>.</mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal" id="cit9"><name name-style="western"><surname>Miyamoto</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Mikami</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Mihara</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Takimoto</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Kohda</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Suzuki</surname><given-names>H.</given-names></name><article-title>Biological activity of fenitrothion and its degradation
products</article-title>. <source>J. Pesticide Sci.</source><year>1978</year>, <volume>3</volume>, <fpage>35</fpage>&#8211;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1584/jpestics.3.35</pub-id>.</mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="journal" id="cit10"><name name-style="western"><surname>Henretig</surname><given-names>F. M.</given-names></name>; <name name-style="western"><surname>Kirk</surname><given-names>M. A.</given-names></name>; <name name-style="western"><surname>McKay</surname><given-names>C. A.</given-names><suffix>Jr.</suffix></name><article-title>Hazardous chemical
emergencies and poisonings</article-title>. <source>N. Engl. J. Med.</source><year>2019</year>, <volume>380</volume> (<issue>17</issue>), <fpage>1638</fpage>&#8211;<lpage>1655</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMra1504690</pub-id>.<pub-id pub-id-type="pmid">31018070</pub-id></mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="undeclared" id="cit11"><source>Fenitrothion: Risk assessment
to support final registration review decision; Memorandum</source>; <publisher-name>US Environmental Protection Agency</publisher-name>: <publisher-loc>Washington DC</publisher-loc>, <year>2010</year>; <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www3.epa.gov/pesticides/chem_search/cleared_reviews/csr_PC-105901_10-Nov-10.pdf">https://www3.epa.gov/pesticides/chem_search/cleared_reviews/csr_PC-105901_10-Nov-10.pdf</uri>.</mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="undeclared" id="cit12"><source>Acute
reference doses
(ARfD) for agricultural and veterinary chemicals used in food producing
crops or animals (Edition 2/2023)</source>; <publisher-name>APVMA
publications; Australian Pesticides and Veterinary Medicines Authority</publisher-name>: <publisher-loc>Sydney, Australia</publisher-loc>, <year>2023</year>; <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://apvma.gov.au/node/98336">https://apvma.gov.au/node/98336</uri>.</mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="undeclared" id="cit13"><source>Pesticide
residues in
food 2007: Joint FAO/WHO Meeting on Pesticide Residues</source>; Report; <publisher-name>Food and Agriculture Organization of the United Nations/World Health
Organization</publisher-name>: <publisher-loc>Rome, Italy</publisher-loc>, <year>2007</year>; <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fao.org/3/a1556e/a1556e.pdf">https://www.fao.org/3/a1556e/a1556e.pdf</uri>.</mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="journal" id="cit14"><name name-style="western"><surname>Dent</surname><given-names>M. P.</given-names></name>; <name name-style="western"><surname>Vaillancourt</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Thomas</surname><given-names>R. S.</given-names></name>; <name name-style="western"><surname>Carmichael</surname><given-names>P. L.</given-names></name>; <name name-style="western"><surname>Ouedraogo</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Kojima</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Barroso</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Ansell</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Barton-Maclaren</surname><given-names>T. S.</given-names></name>; <name name-style="western"><surname>Bennekou</surname><given-names>S. H.</given-names></name>; <name name-style="western"><surname>Boekelheide</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Ezendam</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Field</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Fitzpatrick</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Hatao</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Kreiling</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Lorencini</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Mahony</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Montemayor</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Mazaro-Costa</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Oliveira</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Rogiers</surname><given-names>V.</given-names></name>; <name name-style="western"><surname>Smegal</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Taalman</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Tokura</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Verma</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Willett</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Yang</surname><given-names>C.</given-names></name><article-title>Paving the
way for application of next generation risk assessment to safety decision-making
for cosmetic ingredients</article-title>. <source>Regul. Toxicol. Pharmacol.</source><year>2021</year>, <volume>125</volume>, <elocation-id>105026</elocation-id><pub-id pub-id-type="doi">10.1016/j.yrtph.2021.105026</pub-id>.<pub-id pub-id-type="pmid">34389358</pub-id><pub-id pub-id-type="pmcid">PMC8547713</pub-id></mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal" id="cit15"><name name-style="western"><surname>Paini</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Leonard</surname><given-names>J. A.</given-names></name>; <name name-style="western"><surname>Joossens</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Bessems</surname><given-names>J. G. M.</given-names></name>; <name name-style="western"><surname>Desalegn</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Dorne</surname><given-names>J. L.</given-names></name>; <name name-style="western"><surname>Gosling</surname><given-names>J. P.</given-names></name>; <name name-style="western"><surname>Heringa</surname><given-names>M. B.</given-names></name>; <name name-style="western"><surname>Klaric</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Kliment</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Kramer</surname><given-names>N. I.</given-names></name>; <name name-style="western"><surname>Loizou</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Louisse</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Lumen</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Madden</surname><given-names>J. C.</given-names></name>; <name name-style="western"><surname>Patterson</surname><given-names>E. A.</given-names></name>; <name name-style="western"><surname>Proen&#231;a</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Punt</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Setzer</surname><given-names>R. W.</given-names></name>; <name name-style="western"><surname>Suciu</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Troutman</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Yoon</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Worth</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Tan</surname><given-names>Y. M.</given-names></name><article-title>Next generation
physiologically based kinetic (NG-PBK) models in support of regulatory
decision making</article-title>. <source>Comput. Toxicol.</source><year>2019</year>, <volume>9</volume>, <fpage>61</fpage>&#8211;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1016/j.comtox.2018.11.002</pub-id>.<pub-id pub-id-type="pmid">31008414</pub-id><pub-id pub-id-type="pmcid">PMC6472623</pub-id></mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal" id="cit16"><name name-style="western"><surname>Louisse</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Beekmann</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Rietjens</surname><given-names>I. M. C. M.</given-names></name><article-title>Use
of physiologically based kinetic
modeling-based reverse dosimetry to predict <italic toggle="yes">in vivo</italic> toxicity from <italic toggle="yes">in vitro</italic> data</article-title>. <source>Chem. Res. Toxicol.</source><year>2017</year>, <volume>30</volume>, <fpage>114</fpage>&#8211;<lpage>125</lpage>. <pub-id pub-id-type="doi">10.1021/acs.chemrestox.6b00302</pub-id>.<pub-id pub-id-type="pmid">27768849</pub-id></mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="journal" id="cit17"><name name-style="western"><surname>Shi</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Wesseling</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Bouwmeester</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Rietjens</surname><given-names>I. M. C. M.</given-names></name><article-title>A new approach
methodology (NAM) for the prediction of (nor)ibogaine-induced cardiotoxicity
in humans</article-title>. <source>Altex</source><year>2021</year>, <volume>38</volume> (<issue>4</issue>), <fpage>636</fpage>&#8211;<lpage>652</lpage>. <pub-id pub-id-type="doi">10.14573/altex.2103311</pub-id>.<pub-id pub-id-type="pmid">34271588</pub-id></mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="journal" id="cit18"><name name-style="western"><surname>Zhao</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Kamelia</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Boonpawa</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Wesseling</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Spenkelink</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Rietjens</surname><given-names>I. M. C. M.</given-names></name><article-title>Physiologically based kinetic modeling-facilitated
reverse dosimetry to predict <italic toggle="yes">in vivo</italic> red blood cell
acetylcholinesterase inhibition following exposure to chlorpyrifos
in the Caucasian and Chinese population</article-title>. <source>Toxicol.
Sci.</source><year>2019</year>, <volume>171</volume> (<issue>1</issue>), <fpage>69</fpage>&#8211;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1093/toxsci/kfz134</pub-id>.<pub-id pub-id-type="pmid">31214721</pub-id><pub-id pub-id-type="pmcid">PMC6736452</pub-id></mixed-citation></ref><ref id="ref19"><mixed-citation publication-type="journal" id="cit19"><name name-style="western"><surname>Zhao</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Wesseling</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Rietjens</surname><given-names>I. M. C. M.</given-names></name>; <name name-style="western"><surname>Strikwold</surname><given-names>M.</given-names></name><article-title>Inter-individual
variation in chlorpyrifos toxicokinetics characterized by physiologically
based kinetic (PBK) and Monte Carlo simulation comparing human liver
microsome and Supersome cytochromes P450 (CYP)-specific kinetic data
as model input</article-title>. <source>Arch. Toxicol.</source><year>2022</year>, <volume>96</volume>, <fpage>1387</fpage>&#8211;<lpage>1409</lpage>. <pub-id pub-id-type="doi">10.1007/s00204-022-03251-z</pub-id>.<pub-id pub-id-type="pmid">35294598</pub-id><pub-id pub-id-type="pmcid">PMC9013686</pub-id></mixed-citation></ref><ref id="ref20"><mixed-citation publication-type="journal" id="cit20"><name name-style="western"><surname>Zhao</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Wesseling</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Spenkelink</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Rietjens</surname><given-names>I. M. C. M.</given-names></name><article-title>Physiologically
based kinetic modelling based prediction of <italic toggle="yes">in vivo</italic> rat and human acetylcholinesterase (AChE) inhibition upon exposure
to diazinon</article-title>. <source>Arch. Toxicol.</source><year>2021</year>, <volume>95</volume>, <fpage>1573</fpage>&#8211;<lpage>1593</lpage>. <pub-id pub-id-type="doi">10.1007/s00204-021-03015-1</pub-id>.<pub-id pub-id-type="pmid">33715020</pub-id><pub-id pub-id-type="pmcid">PMC8113213</pub-id></mixed-citation></ref><ref id="ref21"><mixed-citation publication-type="journal" id="cit21"><name name-style="western"><surname>Omwenga</surname><given-names>I.</given-names></name>; <name name-style="western"><surname>Zhao</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Kanja</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Mol</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Rietjens</surname><given-names>I. M. C. M.</given-names></name>; <name name-style="western"><surname>Louisse</surname><given-names>J.</given-names></name><article-title>Prediction of dose-dependent <italic toggle="yes">in vivo</italic> acetylcholinesterase inhibition by profenofos in
rats and humans
using physiologically based kinetic (PBK) modeling-facilitated reverse
dosimetry</article-title>. <source>Arch. Toxicol.</source><year>2021</year>, <volume>95</volume>, <fpage>1287</fpage>&#8211;<lpage>1301</lpage>. <pub-id pub-id-type="doi">10.1007/s00204-021-03004-4</pub-id>.<pub-id pub-id-type="pmid">33651127</pub-id><pub-id pub-id-type="pmcid">PMC8032624</pub-id></mixed-citation></ref><ref id="ref22"><mixed-citation publication-type="journal" id="cit22"><name name-style="western"><surname>Karrer</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>de Boer</surname><given-names>W.</given-names></name>; <name name-style="western"><surname>Delmaar</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Cai</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Cr&#233;pet</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Hungerb&#252;hler</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>von Goetz</surname><given-names>N.</given-names></name><article-title>Linking probabilistic exposure and
pharmacokinetic modeling to assess the cumulative risk from the bisphenols
BPA, BPS, BPF, and BPAF for Europeans</article-title>. <source>Environ.
Sci. Technol.</source><year>2019</year>, <volume>53</volume>, <fpage>9181</fpage>&#8211;<lpage>9191</lpage>. <pub-id pub-id-type="doi">10.1021/acs.est.9b01749</pub-id>.<pub-id pub-id-type="pmid">31294980</pub-id></mixed-citation></ref><ref id="ref23"><mixed-citation publication-type="journal" id="cit23"><name name-style="western"><surname>Chen</surname><given-names>Q.</given-names></name>; <name name-style="western"><surname>Chou</surname><given-names>W. C.</given-names></name>; <name name-style="western"><surname>Lin</surname><given-names>Z.</given-names></name><article-title>Integration of toxicogenomics and
physiologically based pharmacokinetic modeling in human health risk
assessment of perfluorooctane sulfonate</article-title>. <source>Environ.
Sci. Technol.</source><year>2022</year>, <volume>56</volume>, <fpage>3623</fpage>&#8211;<lpage>3633</lpage>. <pub-id pub-id-type="doi">10.1021/acs.est.1c06479</pub-id>.<pub-id pub-id-type="pmid">35194992</pub-id></mixed-citation></ref><ref id="ref24"><mixed-citation publication-type="undeclared" id="cit24"><article-title>Organophosphorus
insecticides: dialkyl phosphate metabolites</article-title>; <source>Summary of National Biomonitoring Program</source>; <publisher-name>Centers for Disease Control and Prevention</publisher-name>: <publisher-loc>Atlanta, GA</publisher-loc>, <year>2017</year>; <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cdc.gov/biomonitoring/OP-DPM_BiomonitoringSummary.html">https://www.cdc.gov/biomonitoring/OP-DPM_BiomonitoringSummary.html</uri>.</mixed-citation></ref><ref id="ref25"><mixed-citation publication-type="journal" id="cit25"><name name-style="western"><surname>Hladk&#225;</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Nos&#225;l</surname><given-names>M.</given-names></name><article-title>The determination
of the exposition to metathion (fenitrotion)
on the basis of excreting its metabolite p-nitro-m-cresol through
urine in rats</article-title>. <source>Int. Arch. Gewerbepathol. Gewerbehyg.</source><year>1967</year>, <volume>23</volume>, <fpage>209</fpage>&#8211;<lpage>214</lpage>. <pub-id pub-id-type="doi">10.1007/BF00368120</pub-id>.<pub-id pub-id-type="pmid">5594557</pub-id></mixed-citation></ref><ref id="ref26"><mixed-citation publication-type="journal" id="cit26"><name name-style="western"><surname>Molla</surname><given-names>M. A. I.</given-names></name>; <name name-style="western"><surname>Furukawa</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Tateishi</surname><given-names>I.</given-names></name>; <name name-style="western"><surname>Katsumata</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Kaneco</surname><given-names>S.</given-names></name><article-title>Mineralization of diazinon with nanosized&#8211;photocatalyst
TiO<sub>2</sub> in water under sunlight irradiation: optimization
of degradation conditions and reaction pathway</article-title>. <source>Environ. Technol.</source><year>2020</year>, <volume>41</volume> (<issue>27</issue>), <fpage>3524</fpage>&#8211;<lpage>3533</lpage>. <pub-id pub-id-type="doi">10.1080/09593330.2019.1615129</pub-id>.<pub-id pub-id-type="pmid">31072234</pub-id></mixed-citation></ref><ref id="ref27"><mixed-citation publication-type="journal" id="cit27"><name name-style="western"><surname>Pan</surname><given-names>X.</given-names></name>; <name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Li</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Zhang</surname><given-names>J. Z. H.</given-names></name>; <name name-style="western"><surname>Ji</surname><given-names>C.</given-names></name><article-title>MolGpka: A
web server for small molecule pKa prediction using a graph-convolutional
neural network</article-title>. <source>J. Chem. Inf. Model.</source><year>2021</year>, <volume>61</volume> (<issue>7</issue>), <fpage>3159</fpage>&#8211;<lpage>3165</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.1c00075</pub-id>.<pub-id pub-id-type="pmid">34251213</pub-id></mixed-citation></ref><ref id="ref28"><mixed-citation publication-type="journal" id="cit28"><name name-style="western"><surname>Punt</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Pinckaers</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Peijnenburg</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Louisse</surname><given-names>J.</given-names></name><article-title>Development of a web-based
toolbox to support Quantitative In-Vitro-to-In-Vivo Extrapolations
(QIVIVE) within nonanimal testing strategies</article-title>. <source>Chem. Res. Toxicol.</source><year>2021</year>, <volume>34</volume>, <fpage>460</fpage>&#8211;<lpage>472</lpage>. <pub-id pub-id-type="doi">10.1021/acs.chemrestox.0c00307</pub-id>.<pub-id pub-id-type="pmid">33382582</pub-id><pub-id pub-id-type="pmcid">PMC7887804</pub-id></mixed-citation></ref><ref id="ref29"><mixed-citation publication-type="journal" id="cit29"><name name-style="western"><surname>Berezhkovskiy</surname><given-names>L. M.</given-names></name><article-title>Volume
of distribution at steady state for a linear pharmacokinetic system
with peripheral elimination</article-title>. <source>J. Pharm. Sci.</source><year>2004</year>, <volume>93</volume> (<issue>6</issue>), <fpage>1628</fpage>&#8211;<lpage>1640</lpage>. <pub-id pub-id-type="doi">10.1002/jps.20073</pub-id>.<pub-id pub-id-type="pmid">15124219</pub-id></mixed-citation></ref><ref id="ref30"><mixed-citation publication-type="journal" id="cit30"><name name-style="western"><surname>Rodgers</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Rowland</surname><given-names>M.</given-names></name><article-title>Physiologically based
pharmacokinetic modelling 2:
Predicting the tissue distribution of acids, very weak bases, neutrals
and zwitterions</article-title>. <source>J. Pharm. Sci.</source><year>2006</year>, <volume>95</volume> (<issue>6</issue>), <fpage>1238</fpage>&#8211;<lpage>1257</lpage>. <pub-id pub-id-type="doi">10.1002/jps.20502</pub-id>.<pub-id pub-id-type="pmid">16639716</pub-id></mixed-citation></ref><ref id="ref31"><mixed-citation publication-type="journal" id="cit31"><name name-style="western"><surname>Punt</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Louisse</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Beekmann</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Pinckaers</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Fabian</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>van Ravenzwaay</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Carmichael</surname><given-names>P. L.</given-names></name>; <name name-style="western"><surname>Sorrell</surname><given-names>I.</given-names></name>; <name name-style="western"><surname>Moxon</surname><given-names>T. E.</given-names></name><article-title>Predictive performance
of next generation
human physiologically based kinetic (PBK) models based on <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in silico</italic> input data</article-title>. <source>Altex</source><year>2022</year>, <volume>39</volume> (<issue>2</issue>), <fpage>221</fpage>&#8211;<lpage>234</lpage>. <pub-id pub-id-type="doi">10.14573/altex.2108301s2</pub-id>.<pub-id pub-id-type="pmid">35064272</pub-id></mixed-citation></ref><ref id="ref32"><mixed-citation publication-type="journal" id="cit32"><name name-style="western"><surname>Badhan</surname><given-names>R. K. S.</given-names></name>; <name name-style="western"><surname>Chenel</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Penny</surname><given-names>J. I.</given-names></name><article-title>Development
of a physiologically-based
pharmacokinetic model of the rat central nervous system</article-title>. <source>Pharmaceutics.</source><year>2014</year>, <volume>6</volume> (<issue>1</issue>), <fpage>97</fpage>&#8211;<lpage>136</lpage>. <pub-id pub-id-type="doi">10.3390/pharmaceutics6010097</pub-id>.<pub-id pub-id-type="pmid">24647103</pub-id><pub-id pub-id-type="pmcid">PMC3978528</pub-id></mixed-citation></ref><ref id="ref33"><mixed-citation publication-type="journal" id="cit33"><name name-style="western"><surname>Zanger</surname><given-names>U. M.</given-names></name>; <name name-style="western"><surname>Schwab</surname><given-names>M.</given-names></name><article-title>Cytochrome P450 enzymes
in drug metabolism: Regulation
of gene expression, enzyme activities, and impact of genetic variation</article-title>. <source>Pharmacol. Ther.</source><year>2013</year>, <volume>138</volume> (<issue>1</issue>), <fpage>103</fpage>&#8211;<lpage>141</lpage>. <pub-id pub-id-type="doi">10.1016/j.pharmthera.2012.12.007</pub-id>.<pub-id pub-id-type="pmid">23333322</pub-id></mixed-citation></ref><ref id="ref34"><mixed-citation publication-type="journal" id="cit34"><name name-style="western"><surname>Poulin</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Haddad</surname><given-names>S.</given-names></name><article-title>A new guidance for
the prediction of hepatic clearance
in the early drug discovery and development from the <italic toggle="yes">in vitro</italic>-to-<italic toggle="yes">in vivo</italic> extrapolation method and an approach
for exploring whether an albumin-mediated hepatic uptake phenomenon
could be presentunder in vivo conditions</article-title>. <source>J.
Pharm. Sci.</source><year>2021</year>, <volume>110</volume>, <fpage>2841</fpage>&#8211;<lpage>2858</lpage>. <pub-id pub-id-type="doi">10.1016/j.xphs.2021.04.002</pub-id>.<pub-id pub-id-type="pmid">33857483</pub-id></mixed-citation></ref><ref id="ref35"><mixed-citation publication-type="journal" id="cit35"><name name-style="western"><surname>Medinsky</surname><given-names>M. A.</given-names></name>; <name name-style="western"><surname>Leavens</surname><given-names>T. L.</given-names></name>; <name name-style="western"><surname>Csan&#225;dy</surname><given-names>G. A.</given-names></name>; <name name-style="western"><surname>Gargas</surname><given-names>M. L.</given-names></name>; <name name-style="western"><surname>Bond</surname><given-names>J. A.</given-names></name><article-title><italic toggle="yes">In vivo</italic> metabolism of butadiene by mice and rats: A comparison
of physiological model predictions and experimental data</article-title>. <source>Carcinogenesis.</source><year>1994</year>, <volume>15</volume> (<issue>7</issue>), <fpage>1329</fpage>&#8211;<lpage>1340</lpage>. <pub-id pub-id-type="doi">10.1093/carcin/15.7.1329</pub-id>.<pub-id pub-id-type="pmid">8033308</pub-id></mixed-citation></ref><ref id="ref36"><mixed-citation publication-type="journal" id="cit36"><name name-style="western"><surname>Barter</surname><given-names>Z. E.</given-names></name>; <name name-style="western"><surname>Bayliss</surname><given-names>M. K.</given-names></name>; <name name-style="western"><surname>Beaune</surname><given-names>P. H.</given-names></name>; <name name-style="western"><surname>Boobis</surname><given-names>A. R.</given-names></name>; <name name-style="western"><surname>Carlile</surname><given-names>D. J.</given-names></name>; <name name-style="western"><surname>Edwards</surname><given-names>R. J.</given-names></name>; <name name-style="western"><surname>Houston</surname><given-names>J. B.</given-names></name>; <name name-style="western"><surname>Lake</surname><given-names>B. G.</given-names></name>; <name name-style="western"><surname>Lipscomb</surname><given-names>J. C.</given-names></name>; <name name-style="western"><surname>Pelkonen</surname><given-names>O. R.</given-names></name>; <name name-style="western"><surname>Tucker</surname><given-names>G. T.</given-names></name>; <name name-style="western"><surname>Rostami-Hodjegan</surname><given-names>A.</given-names></name><article-title>Scaling factors
for the extrapolation of <italic toggle="yes">in vivo</italic> metabolic drug clearance
from <italic toggle="yes">in vitro</italic> data: reaching a consensus on values
of human microsomal protein and hepatocellularity per gram of liver</article-title>. <source>Curr. Drug Metab.</source><year>2007</year>, <volume>8</volume> (<issue>1</issue>), <fpage>33</fpage>&#8211;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.2174/138920007779315053</pub-id>.<pub-id pub-id-type="pmid">17266522</pub-id></mixed-citation></ref><ref id="ref37"><mixed-citation publication-type="journal" id="cit37"><name name-style="western"><surname>Leoni</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Balduzzi</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Buratti</surname><given-names>F. M.</given-names></name>; <name name-style="western"><surname>Testai</surname><given-names>E.</given-names></name><article-title>The contribution
of
human small intestine to chlorpyrifos biotransformation</article-title>. <source>Toxicol. Lett.</source><year>2012</year>, <volume>215</volume> (<issue>1</issue>), <fpage>42</fpage>&#8211;<lpage>48</lpage>. <pub-id pub-id-type="doi">10.1016/j.toxlet.2012.09.016</pub-id>.<pub-id pub-id-type="pmid">23036741</pub-id></mixed-citation></ref><ref id="ref38"><mixed-citation publication-type="journal" id="cit38"><name name-style="western"><surname>Davies</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Morris</surname><given-names>T.</given-names></name><article-title>Physiological parameters
in laboratory animals and
humans</article-title>. <source>Pharm. Res.</source><year>1993</year>, <volume>10</volume> (<issue>7</issue>), <fpage>1093</fpage>&#8211;<lpage>1095</lpage>. <pub-id pub-id-type="doi">10.1023/A:1018943613122</pub-id>.<pub-id pub-id-type="pmid">8378254</pub-id></mixed-citation></ref><ref id="ref39"><mixed-citation publication-type="journal" id="cit39"><name name-style="western"><surname>Nos&#225;l</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Hladk&#225;</surname><given-names>A.</given-names></name><article-title>Determination
of the exposure to fenitrothion (O,O-dimethyl-O/3-methyl-4-nitrophenyl/thiophosphate)
on the basis of the excretion of p-nitro-m-cresol by the urine of
the persons tested</article-title>. <source>Int. Arch. Gewerbepathol.
Gewerbehyg.</source><year>1968</year>, <volume>25</volume>, <fpage>28</fpage>&#8211;<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1007/BF00404665</pub-id>.<pub-id pub-id-type="pmid">5713132</pub-id></mixed-citation></ref><ref id="ref40"><mixed-citation publication-type="undeclared" id="cit40"><source>Characterization
and
application of physiologically based pharmacokinetic models in risk
assessment; International Programme on Chemical Safety (IPCS), harmonization
project document no. 9</source>; <publisher-name>World Health Organization</publisher-name>: <publisher-loc>Geneva, Switzerland</publisher-loc>, <year>2010</year>; <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/publications/i/item/9789241500906">https://www.who.int/publications/i/item/9789241500906</uri>.</mixed-citation></ref><ref id="ref41"><mixed-citation publication-type="journal" id="cit41"><name name-style="western"><surname>Miyamoto</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Mihara</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Hosokawa</surname><given-names>S.</given-names></name><article-title>Comparative metabolism
of m-methyl-<sup>14</sup>C-Sumithion in several species of mammals <italic toggle="yes">in vivo</italic></article-title>. <source>J. Pestic. Sci.</source><year>1976</year>, <volume>1</volume>, <fpage>9</fpage>&#8211;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1584/jpestics.1.9</pub-id>.</mixed-citation></ref><ref id="ref42"><mixed-citation publication-type="journal" id="cit42"><name name-style="western"><surname>Miyamoto</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Mihara</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Kadota</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Okuno</surname><given-names>Y.</given-names></name><article-title>Toxicity and metabolism <italic toggle="yes">in vivo</italic> of fenitrothion
in rats with experimental hepatic
lesion</article-title>. <source>J. Pestic. Sci.</source><year>1977</year>, <volume>2</volume>, <fpage>271</fpage>&#8211;<lpage>277</lpage>. <pub-id pub-id-type="doi">10.1584/jpestics.2.271</pub-id>.</mixed-citation></ref><ref id="ref43"><mixed-citation publication-type="journal" id="cit43"><name name-style="western"><surname>Meaklim</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Drummer</surname><given-names>O. H.</given-names></name>; <name name-style="western"><surname>Killalea</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Staikos</surname><given-names>V.</given-names></name>; <name name-style="western"><surname>Horomidis</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Rutherford</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Ioannides-Demos</surname><given-names>L. L.</given-names></name>; <name name-style="western"><surname>Lim</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>McLean</surname><given-names>A. J.</given-names></name>; <name name-style="western"><surname>McNeil</surname><given-names>J. J.</given-names></name><article-title>Fenitrothion: Toxicokinetics and
toxicologic evaluation in human volunteers</article-title>. <source>Environ. Health Perspect.</source><year>2003</year>, <volume>111</volume>, <fpage>305</fpage>&#8211;<lpage>308</lpage>. <pub-id pub-id-type="doi">10.1289/ehp.5726</pub-id>.<pub-id pub-id-type="pmid">12611659</pub-id><pub-id pub-id-type="pmcid">PMC1241387</pub-id></mixed-citation></ref><ref id="ref44"><mixed-citation publication-type="undeclared" id="cit44"><person-group person-group-type="allauthors"><name name-style="western"><surname>Beyrouty</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Benjamin</surname><given-names>W.</given-names></name>; <name name-style="western"><surname>Robinson</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Noveroske</surname><given-names>J.</given-names></name></person-group><source>A 3-month dietary study
of the potential effects of fenitrothion on behaviour, neurochemistry,
neuromorphology in rats</source>; Unpublished report (no. HT-31&#8211;0520); <publisher-name>Sumitomo Chemical Co., Ltd.</publisher-name>: <publisher-loc>Osaka,
Japan</publisher-loc>, <year>1993</year>; <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://inchem.org/documents/jmpr/jmpmono/v00pr06.htm">https://inchem.org/documents/jmpr/jmpmono/v00pr06.htm</uri>.</mixed-citation></ref><ref id="ref45"><mixed-citation publication-type="journal" id="cit45"><name name-style="western"><surname>Kadota</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Kohda</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Miyamoto</surname><given-names>J.</given-names></name><article-title>Subchronic
toxicity studies of sumithion,
sumioxon and p-nitrocresol in rats and 92 week feeding study of sumithion
with special reference to change of cholinesterase activity</article-title>. <source>Botyu-Kagaku (Sci. Pest Control)</source><year>1975</year>, <volume>40</volume> (<issue>2</issue>), <fpage>38</fpage>&#8211;<lpage>48</lpage>.</mixed-citation></ref><ref id="ref46"><mixed-citation publication-type="journal" id="cit46"><name name-style="western"><surname>Buratti</surname><given-names>F. M.</given-names></name>; <name name-style="western"><surname>Leoni</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Testai</surname><given-names>E.</given-names></name><article-title>The human
metabolism of organophosphorothionate
pesticides: Consequences for toxicological risk assessment</article-title>. <source>J. Verbr. Lebensm.</source><year>2007</year>, <volume>2</volume>, <fpage>37</fpage>&#8211;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1007/s00003-006-0109-z</pub-id>.</mixed-citation></ref><ref id="ref47"><mixed-citation publication-type="journal" id="cit47"><name name-style="western"><surname>Levi</surname><given-names>P. E.</given-names></name>; <name name-style="western"><surname>Hollingworth</surname><given-names>R. M.</given-names></name>; <name name-style="western"><surname>Hodgson</surname><given-names>E.</given-names></name><article-title>Differences in oxidative
dearylation
and desulfuration of fenitrothion by cytochrome P-450 isozymes and
in the subsequent inhibition of monooxygenase activity</article-title>. <source>Pestic. Biochem. Physiol.</source><year>1988</year>, <volume>32</volume>, <fpage>224</fpage>&#8211;<lpage>231</lpage>. <pub-id pub-id-type="doi">10.1016/0048-3575(88)90105-8</pub-id>.</mixed-citation></ref><ref id="ref48"><mixed-citation publication-type="journal" id="cit48"><name name-style="western"><surname>Xiao</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Xue</surname><given-names>X.</given-names></name>; <name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Xin</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Qian</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Xie</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Gong</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Ren</surname><given-names>J.</given-names></name><article-title>&#946;-Naphthoflavone
protects mice
from aristolochic acid-I-induced acute kidney injury in a CYP1A dependent
mechanism</article-title>. <source>Acta Pharmacol. Sin.</source><year>2009</year>, <volume>30</volume>, <fpage>1559</fpage>&#8211;<lpage>1565</lpage>. <pub-id pub-id-type="doi">10.1038/aps.2009.156</pub-id>.<pub-id pub-id-type="pmid">19890363</pub-id><pub-id pub-id-type="pmcid">PMC4003015</pub-id></mixed-citation></ref><ref id="ref49"><mixed-citation publication-type="journal" id="cit49"><name name-style="western"><surname>Sakuma</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Ohtake</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Katsurayama</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Jarukamjorn</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Nemoto</surname><given-names>N.</given-names></name><article-title>Induction of CYP1A2 by phenobarbital
in the livers
of aryl hydrocarbon-responsive and -nonresponsive mice</article-title>. <source>Drug Metab. Dispos.</source><year>1999</year>, <volume>27</volume> (<issue>3</issue>), <fpage>379</fpage>&#8211;<lpage>384</lpage>.<pub-id pub-id-type="pmid">10064569</pub-id></mixed-citation></ref><ref id="ref50"><mixed-citation publication-type="journal" id="cit50"><name name-style="western"><surname>Nelson</surname><given-names>D. R.</given-names></name>; <name name-style="western"><surname>Zeldin</surname><given-names>D. C.</given-names></name>; <name name-style="western"><surname>Hoffman</surname><given-names>S. M. G.</given-names></name>; <name name-style="western"><surname>Maltais</surname><given-names>L. J.</given-names></name>; <name name-style="western"><surname>Wain</surname><given-names>H. M.</given-names></name>; <name name-style="western"><surname>Nebert</surname><given-names>D. W.</given-names></name><article-title>Comparison of cytochrome P450 (CYP) genes from the
mouse and human genomes, including nomenclature recommendations for
genes, pseudogenes and alternative-splice variants</article-title>. <source>Pharmacogenet.</source><year>2004</year>, <volume>14</volume> (<issue>1</issue>), <fpage>1</fpage>&#8211;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1097/00008571-200401000-00001</pub-id>.<pub-id pub-id-type="pmid">15128046</pub-id></mixed-citation></ref><ref id="ref51"><mixed-citation publication-type="journal" id="cit51"><name name-style="western"><surname>Ellison</surname><given-names>C. A.</given-names></name>; <name name-style="western"><surname>Tian</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Knaak</surname><given-names>J. B.</given-names></name>; <name name-style="western"><surname>Kostyniak</surname><given-names>P. J.</given-names></name>; <name name-style="western"><surname>Olson</surname><given-names>J. R.</given-names></name><article-title>Human hepatic cytochrome P450-specific
metabolism of
the organophosphorus pesticides methyl parathion and diazinon</article-title>. <source>Drug Metab. Dispos.</source><year>2012</year>, <volume>40</volume> (<issue>1</issue>), <fpage>1</fpage>&#8211;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1124/dmd.111.042572</pub-id>.<pub-id pub-id-type="pmid">21969518</pub-id><pub-id pub-id-type="pmcid">PMC3250044</pub-id></mixed-citation></ref><ref id="ref52"><mixed-citation publication-type="journal" id="cit52"><name name-style="western"><surname>Sams</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Mason</surname><given-names>H. J.</given-names></name>; <name name-style="western"><surname>Rawbone</surname><given-names>R.</given-names></name><article-title>Evidence for
the activation of organophosphate
pesticides by cytochromes P450 3A4 and 2D6 in human liver microsomes</article-title>. <source>Toxicol. Lett.</source><year>2000</year>, <volume>116</volume> (<issue>3</issue>), <fpage>217</fpage>&#8211;<lpage>221</lpage>. <pub-id pub-id-type="doi">10.1016/S0378-4274(00)00221-6</pub-id>.<pub-id pub-id-type="pmid">10996483</pub-id></mixed-citation></ref><ref id="ref53"><mixed-citation publication-type="journal" id="cit53"><name name-style="western"><surname>Sinan</surname><given-names>S.</given-names></name><article-title><italic toggle="yes">In
vitro</italic> inhibition of the paraoxonase from human serum with
sulfonamide</article-title>. <source>Afr. J. Biotechnol.</source><year>2008</year>, <volume>7</volume> (<issue>5</issue>), <fpage>508</fpage>&#8211;<lpage>512</lpage>. <pub-id pub-id-type="doi">10.5897/AJB07.711</pub-id>.</mixed-citation></ref><ref id="ref54"><mixed-citation publication-type="journal" id="cit54"><name name-style="western"><surname>Carr</surname><given-names>R. L.</given-names></name>; <name name-style="western"><surname>Dail</surname><given-names>M. B.</given-names></name>; <name name-style="western"><surname>Chambers</surname><given-names>H. W.</given-names></name>; <name name-style="western"><surname>Chambers</surname><given-names>J. E.</given-names></name><article-title>Species differences
in paraoxonase mediated hydrolysis of several organophosphorus insecticide
metabolites</article-title>. <source>J. Toxicol.</source><year>2015</year>, <volume>2015</volume>, <fpage>1</fpage>&#8211;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1155/2015/470189</pub-id>.<pub-id pub-id-type="pmcid">PMC4345044</pub-id><pub-id pub-id-type="pmid">25784934</pub-id></mixed-citation></ref><ref id="ref55"><mixed-citation publication-type="journal" id="cit55"><name name-style="western"><surname>Moser</surname><given-names>V. C.</given-names></name>; <name name-style="western"><surname>Padilla</surname><given-names>S.</given-names></name><article-title>Esterase detoxication
of acetylcholinesterase inhibitors
using human liver samples <italic toggle="yes">in vitro</italic></article-title>. <source>Toxicol.</source><year>2016</year>, <volume>353&#8211;354</volume>, <fpage>11</fpage>&#8211;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1016/j.tox.2016.04.006</pub-id>.<pub-id pub-id-type="pmid">27132127</pub-id></mixed-citation></ref><ref id="ref56"><mixed-citation publication-type="journal" id="cit56"><name name-style="western"><surname>Darney</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Kasteel</surname><given-names>E. E. J.</given-names></name>; <name name-style="western"><surname>Buratti</surname><given-names>F. M.</given-names></name>; <name name-style="western"><surname>Turco</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Vichi</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>B&#233;chaux</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Roudot</surname><given-names>A. C.</given-names></name>; <name name-style="western"><surname>Kramer</surname><given-names>N. I.</given-names></name>; <name name-style="western"><surname>Testai</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Dorne</surname><given-names>J. L. C. M.</given-names></name>; <name name-style="western"><surname>Di Consiglio</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Lautz</surname><given-names>L. S.</given-names></name><article-title>Bayesian meta-analysis
of inter-phenotypic differences in human serum paraoxonase-1 activity
for chemical risk assessment</article-title>. <source>Environ. Int.</source><year>2020</year>, <volume>138</volume>, <elocation-id>105609</elocation-id><pub-id pub-id-type="doi">10.1016/j.envint.2020.105609</pub-id>.<pub-id pub-id-type="pmid">32114288</pub-id></mixed-citation></ref><ref id="ref57"><mixed-citation publication-type="journal" id="cit57"><name name-style="western"><surname>Feng</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>LaPerle</surname><given-names>J. L.</given-names></name>; <name name-style="western"><surname>Chang</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Varma</surname><given-names>M. V. S.</given-names></name><article-title>Renal clearance
in drug discovery and development: molecular descriptors, drug transporters
and disease state</article-title>. <source>Expert Opin. Drug Metab.
Toxicol.</source><year>2010</year>, <volume>6</volume> (<issue>8</issue>), <fpage>939</fpage>&#8211;<lpage>952</lpage>. <pub-id pub-id-type="doi">10.1517/17425255.2010.482930</pub-id>.<pub-id pub-id-type="pmid">20433402</pub-id></mixed-citation></ref><ref id="ref58"><mixed-citation publication-type="journal" id="cit58"><name name-style="western"><surname>Moon</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Chun</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Lee</surname><given-names>S.</given-names></name><article-title>Variable response of
cholinesterase
activities following human exposure to different types of organophosphates</article-title>. <source>Hum. Exp. Toxicol.</source><year>2015</year>, <volume>34</volume> (<issue>7</issue>), <fpage>698</fpage>&#8211;<lpage>706</lpage>. <pub-id pub-id-type="doi">10.1177/0960327114558890</pub-id>.<pub-id pub-id-type="pmid">25712411</pub-id></mixed-citation></ref><ref id="ref59"><mixed-citation publication-type="journal" id="cit59"><name name-style="western"><surname>Lockridge</surname><given-names>O.</given-names></name>; <name name-style="western"><surname>Norgren</surname><given-names>R. B.</given-names><suffix>Jr.</suffix></name>; <name name-style="western"><surname>Johnson</surname><given-names>R. C.</given-names></name>; <name name-style="western"><surname>Blake</surname><given-names>T. A.</given-names></name><article-title>Naturally
occurring genetic variants of human acetylcholinesterase and butyrylcholinesterase
and their potential impact on the risk of toxicity from cholinesterase
inhibitors</article-title>. <source>Chem. Res. Toxicol.</source><year>2016</year>, <volume>29</volume> (<issue>9</issue>), <fpage>1381</fpage>&#8211;<lpage>1392</lpage>. <pub-id pub-id-type="doi">10.1021/acs.chemrestox.6b00228</pub-id>.<pub-id pub-id-type="pmid">27551784</pub-id><pub-id pub-id-type="pmcid">PMC5030680</pub-id></mixed-citation></ref><ref id="ref60"><mixed-citation publication-type="book" id="cit60"><source>The use of data
on cholinesterase inhibition for risk assessments
of organophosphorous and carbamate pesticides</source>; Science policy; <publisher-name>US Environmental Protection Agency</publisher-name>: <publisher-loc>Washington DC</publisher-loc>, <year>2000</year>; <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.epa.gov/sites/default/files/2015-07/documents/cholin.pdf">https://www.epa.gov/sites/default/files/2015-07/documents/cholin.pdf</uri>.</mixed-citation></ref><ref id="ref61"><mixed-citation publication-type="journal" id="cit61"><name name-style="western"><surname>van
Gemert</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Dourson</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Moretto</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Watson</surname><given-names>M.</given-names></name><article-title>Use of human
data for the derivation of a reference dose for chlorpyrifos</article-title>. <source>Regul. Toxicol. Pharmacol.</source><year>2001</year>, <volume>33</volume> (<issue>2</issue>), <fpage>110</fpage>&#8211;<lpage>116</lpage>. <pub-id pub-id-type="doi">10.1006/rtph.2000.1447</pub-id>.<pub-id pub-id-type="pmid">11350194</pub-id></mixed-citation></ref><ref id="ref62"><mixed-citation publication-type="journal" id="cit62"><name name-style="western"><surname>Kasteel</surname><given-names>E. E. J.</given-names></name>; <name name-style="western"><surname>Nijmeijer</surname><given-names>S. M.</given-names></name>; <name name-style="western"><surname>Darney</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Lautz</surname><given-names>L. S.</given-names></name>; <name name-style="western"><surname>Dorne</surname><given-names>J. L. C. M.</given-names></name>; <name name-style="western"><surname>Kramer</surname><given-names>N. I.</given-names></name>; <name name-style="western"><surname>Westerink</surname><given-names>R. H. S.</given-names></name><article-title>Acetylcholinesterase inhibition in
electric eel and human donor blood: An <italic toggle="yes">in vitro</italic> approach
to investigate interspecies differences and human variability in toxicodynamics</article-title>. <source>Arch. Toxicol.</source><year>2020</year>, <volume>94</volume>, <fpage>4055</fpage>&#8211;<lpage>4065</lpage>. <pub-id pub-id-type="doi">10.1007/s00204-020-02927-8</pub-id>.<pub-id pub-id-type="pmid">33037899</pub-id><pub-id pub-id-type="pmcid">PMC7655571</pub-id></mixed-citation></ref><ref id="ref63"><mixed-citation publication-type="journal" id="cit63"><name name-style="western"><surname>Haber</surname><given-names>L. T.</given-names></name>; <name name-style="western"><surname>Dourson</surname><given-names>M. L.</given-names></name>; <name name-style="western"><surname>Allen</surname><given-names>B. C.</given-names></name>; <name name-style="western"><surname>Hertzberg</surname><given-names>R. C.</given-names></name>; <name name-style="western"><surname>Parker</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Vincent</surname><given-names>M. J.</given-names></name>; <name name-style="western"><surname>Maier</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Boobis</surname><given-names>A. R.</given-names></name><article-title>Benchmark
dose (BMD) modeling: Current practice, issues, and challenges</article-title>. <source>Crit. Rev. Toxicol.</source><year>2018</year>, <volume>48</volume> (<issue>5</issue>), <fpage>387</fpage>&#8211;<lpage>415</lpage>. <pub-id pub-id-type="doi">10.1080/10408444.2018.1430121</pub-id>.<pub-id pub-id-type="pmid">29516780</pub-id></mixed-citation></ref><ref id="ref64"><mixed-citation publication-type="journal" id="cit64"><name name-style="western"><surname>Ross</surname><given-names>M. K.</given-names></name>; <name name-style="western"><surname>Streit</surname><given-names>T. M.</given-names></name>; <name name-style="western"><surname>Herring</surname><given-names>K. L.</given-names></name><article-title>Carboxylesterases:
Dual roles in
lipid and pesticide metabolism</article-title>. <source>J. Pestic. Sci.</source><year>2010</year>, <volume>35</volume> (<issue>3</issue>), <fpage>257</fpage>&#8211;<lpage>264</lpage>. <pub-id pub-id-type="doi">10.1584/jpestics.R10-07</pub-id>.<pub-id pub-id-type="pmid">25018661</pub-id><pub-id pub-id-type="pmcid">PMC4087164</pub-id></mixed-citation></ref><ref id="ref65"><mixed-citation publication-type="journal" id="cit65"><name name-style="western"><surname>Li</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Sedlacek</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Manoharan</surname><given-names>I.</given-names></name>; <name name-style="western"><surname>Boopathy</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Duysen</surname><given-names>E. G.</given-names></name>; <name name-style="western"><surname>Masson</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Lockridge</surname><given-names>O.</given-names></name><article-title>Butyrylcholinesterase,
paraoxonase,
and albumin esterase, but not carboxylesterase, are present in human
plasma</article-title>. <source>Biochem. Pharmacol.</source><year>2005</year>, <volume>70</volume> (<issue>11</issue>), <fpage>1673</fpage>&#8211;<lpage>1684</lpage>. <pub-id pub-id-type="doi">10.1016/j.bcp.2005.09.002</pub-id>.<pub-id pub-id-type="pmid">16213467</pub-id></mixed-citation></ref><ref id="ref66"><mixed-citation publication-type="journal" id="cit66"><name name-style="western"><surname>Hladk&#225;</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Hladk&#253;</surname><given-names>Z.</given-names></name><article-title>Separation
of <italic toggle="yes">p</italic>-nitrophenol and <italic toggle="yes">p</italic>-nitro-m-cresol
from urine pigments by thin layer chromatography</article-title>. <source>J. Chromatogr. A</source><year>1966</year>, <volume>22</volume>, <fpage>457</fpage>&#8211;<lpage>459</lpage>. <pub-id pub-id-type="doi">10.1016/S0021-9673(01)97123-7</pub-id>.<pub-id pub-id-type="pmid">5961140</pub-id></mixed-citation></ref><ref id="ref67"><mixed-citation publication-type="journal" id="cit67"><name name-style="western"><surname>Hladk&#225;</surname><given-names>A.</given-names></name><article-title>Determination
of <italic toggle="yes">p</italic>-nitro-m-cresol in human urine</article-title>. <source>Fresenius&#8217; Z. Anal. Chem.</source><year>1969</year>, <volume>245</volume>, <fpage>389</fpage><pub-id pub-id-type="doi">10.1007/BF00423953</pub-id>.</mixed-citation></ref><ref id="ref68"><mixed-citation publication-type="journal" id="cit68"><name name-style="western"><surname>Mangas</surname><given-names>I.</given-names></name>; <name name-style="western"><surname>Estevez</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Vilanova</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Fran&#231;a</surname><given-names>T. C. C.</given-names></name><article-title>New
insights on molecular interactions of organophosphorus pesticides
with esterases</article-title>. <source>Toxicol.</source><year>2017</year>, <volume>376</volume>, <fpage>30</fpage>&#8211;<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1016/j.tox.2016.06.006</pub-id>.<pub-id pub-id-type="pmid">27311923</pub-id></mixed-citation></ref><ref id="ref69"><mixed-citation publication-type="journal" id="cit69"><name name-style="western"><surname>Traina</surname><given-names>M. E.</given-names></name>; <name name-style="western"><surname>Serpietri</surname><given-names>L. A.</given-names></name><article-title>Changes
in the levels and forms of rat plasma cholinesterases
during chronic diisopropylphosphorofluoridate intoxication</article-title>. <source>Biochem. Pharmacol.</source><year>1984</year>, <volume>33</volume> (<issue>4</issue>), <fpage>645</fpage>&#8211;<lpage>653</lpage>. <pub-id pub-id-type="doi">10.1016/0006-2952(84)90321-6</pub-id>.<pub-id pub-id-type="pmid">6704181</pub-id></mixed-citation></ref><ref id="ref70"><mixed-citation publication-type="journal" id="cit70"><name name-style="western"><surname>Garc&#237;a-Ayll&#243;n</surname><given-names>M. S.</given-names></name>; <name name-style="western"><surname>Silveyra</surname><given-names>M. X.</given-names></name>; <name name-style="western"><surname>Candela</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Compa&#241;</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Cl&#224;ria</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Jover</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>P&#233;rez-Mateo</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Felipo</surname><given-names>V.</given-names></name>; <name name-style="western"><surname>Mart&#237;nez</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Galcer&#225;n</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>S&#225;ez-Valero</surname><given-names>J.</given-names></name><article-title>Changes in liver and plasma acetylcholinesterase in
rats with cirrhosis induced by bile duct ligation</article-title>. <source>Hepatology.</source><year>2006</year>, <volume>43</volume> (<issue>3</issue>), <fpage>444</fpage>&#8211;<lpage>453</lpage>. <pub-id pub-id-type="doi">10.1002/hep.21071</pub-id>.<pub-id pub-id-type="pmid">16496349</pub-id></mixed-citation></ref><ref id="ref71"><mixed-citation publication-type="journal" id="cit71"><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name>; <name name-style="western"><surname>Li</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Middleton</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Bhattacharya</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Conolly</surname><given-names>R. B.</given-names></name><article-title>Bridging the data
gap from <italic toggle="yes">in vitro</italic> toxicity testing to chemical safety
assessment through computational modeling</article-title>. <source>Front.
Public Health.</source><year>2018</year>, <volume>6</volume>, <fpage>261</fpage><pub-id pub-id-type="doi">10.3389/fpubh.2018.00261</pub-id>.<pub-id pub-id-type="pmid">30255008</pub-id><pub-id pub-id-type="pmcid">PMC6141783</pub-id></mixed-citation></ref><ref id="ref72"><mixed-citation publication-type="journal" id="cit72"><name name-style="western"><surname>Poet</surname><given-names>T. S.</given-names></name>; <name name-style="western"><surname>Kousba</surname><given-names>A. A.</given-names></name>; <name name-style="western"><surname>Dennison</surname><given-names>S. L.</given-names></name>; <name name-style="western"><surname>Timchalk</surname><given-names>C.</given-names></name><article-title>Physiologically
based
pharmacokinetic/pharmacodynamic model for the organophosphorus pesticide
diazinon</article-title>. <source>NeuroToxicology.</source><year>2004</year>, <volume>25</volume> (<issue>6</issue>), <fpage>1013</fpage>&#8211;<lpage>1030</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuro.2004.03.002</pub-id>.<pub-id pub-id-type="pmid">15474619</pub-id></mixed-citation></ref><ref id="ref73"><mixed-citation publication-type="journal" id="cit73"><name name-style="western"><surname>Poet</surname><given-names>T. S.</given-names></name>; <name name-style="western"><surname>Timchalk</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Bartels</surname><given-names>M. J.</given-names></name>; <name name-style="western"><surname>Smith</surname><given-names>J. N.</given-names></name>; <name name-style="western"><surname>McDougal</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Juberg</surname><given-names>D. R.</given-names></name>; <name name-style="western"><surname>Price</surname><given-names>P. S.</given-names></name><article-title>Use of
a probabilistic PBPK/PD model
to calculate data derived extrapolation factors for chlorpyrifos</article-title>. <source>Regul. Toxicol. Pharmacol.</source><year>2017</year>, <volume>86</volume>, <fpage>59</fpage>&#8211;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1016/j.yrtph.2017.02.014</pub-id>.<pub-id pub-id-type="pmid">28238854</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>